RESEARCH ARTICLE

Synthesis, characterization and in vitro antitrypanosomal activities of new carboxamides bearing quinoline moiety

David Izuchukwu Ugwu¹,²*, Uchechukwu Chris Okoro¹, Narendra Kumar Mishra²

¹ Medicinal Chemistry Unit, Department of Pure and Industrial Chemistry, University of Nigeria, Nsukka, Nigeria, ² Department of Chemistry, Indian Institute of Technology, Kanpur, India

* izuchukwu.ugwu@unn.edu.ng

Abstract

The reported toxicities of current antitrypanosomal drugs and the emergence of drug resistant trypanosomes underscore the need for the development of new antitrypanosomal agents. We report herein the synthesis and antitrypanosomal activity of 24 new amide derivatives of 3-aminoquinoline, bearing substituted benzenesulphonamide. Nine of the new derivatives showed comparable antitrypanosomal activities at IC₅₀ range of 1–6 nM (melarsoprol 5 nM). Compound 11h and 11v are more promising antitrypanosomal agents with IC₅₀ 1.0 nM than the rest of the reported derivatives. The novel compounds showed satisfactory predicted physico-chemical properties including oral bioavailability, permeability and transport properties.

Introduction

Trypanosomes are parasitic protozoa that cause Chagas disease in central and South America and sleeping sickness in sub-Saharan Africa leading to morbidity and mortality of millions of people [1]. Trypanosoma brucei gambiense and T. b. rhodesiense are the etiological agents of sleeping sickness in humans in sub-Saharan Africa. About half a million people are infected with sleeping sickness leading to the death of almost 100,000 people annually [2]. Despite the fact that in the past 24 years, the number of incidence for both Chagas and human African trypanosomiasis (HAT) has significantly declined, primarily due to vector control initiatives [3], the development of new chemotherapeutic agent for the treatment of sleeping sickness and Chagas disease is urgently needed because of the undesirable toxic side effects of known antitrypanosomal drugs, and the emergence of drug-resistant trypanosomes.

Benznidazole (1), melarsoprol (2), pentamidine (3) and nifurtimox (4) are the leading chemotherapeutic agent used in the treatment of Chagas and sleeping sickness. Benznidazole (1) is primarily used for the treatment of Chagas disease. Melarsoprol (2) has a high number of associated side effects [4] including but not limited to brain dysfunction, convulsion, numbness, rashes, kidney and liver problems [5]. About 1–5% of people die from adverse effects related to melarsoprol treatment [6]. Pentamidine (3) is usually applied at the early stage of the parasite before it crosses to central nervous system. It is not recommended in early pregnancy...
because of the associated side effects [7]. The most common side effects of concern is wheezing, hypotension, severe arrhythmias and heart failure [8, 9]. Pentamidine has also been linked to azotemia, renal failure, hepatomegaly, hepatitis, seizures and hypoglycemia [9]. In addition to the side effects of pentamidine, it is also costly with the inhalation powder costing up to 122.84 USD and a vial for injection costing 45.31 USD in the United States [10]. Nifurtimox (4) takes 30 to 60 days administration to treat Chagas disease [11]. This long term use does increase chances of adverse effects like gastrointestinal and neurological disorder [12]. It is also reported that administration of nifurtimox in sleeping sickness leads to relapsing in half of the patients treated [13]. The use of nifurtimox in pregnancy is usually avoided because of the associated side effects [14]. Nifurtimox has also been linked to central nervous system disturbances, peripheral neuropathy, confusion, seizures, impotency, depression and numbness [15–17]. Eflornithine (5) is the only new drug introduced for the treatment of sleeping sickness but was ineffective against T. b. rhodesiense [18].

As there is no immediate prospect for vaccines, chemotherapy is the only way to fight trypanosomes. This enzyme is responsible for the major proteolytic activity of all life cycle stages of this parasite [19]. Brucipain is localized in the lysosomes of blood stream forms of T. brucei [20]. It induces calcium activation signals that allows blood brain barrier to open up to parasite crossing [21]. This makes this enzyme a good target for the treatment of human African trypanosomiasis.

In line with the call for the synthesis of new chemotherapeutic agent for the treatment of human African trypanosomiasis, Ajibade and Kolawole [22] reported antitrypanosomal activities of some sulfadiazine complex. Papadopoulou et al [23] also reported the antitrypanosomal activities of some amides and sulphonamides. Some of the derivatives reported by this group were more potent up to 58-fold than benznidazole (1).

Since benznidazole (1) contains an amide functionality and nifurtimox (4) contains a sulphone group, synergistic antitrypanosomal activity arising from successful combination of amide of benznidazole and sulphone of nifurtimox motivated this research. This expectation was supported by the work of Papadopoulou which showed comparable antitrypanosomal activity when amide groups were replaced with sulphonamides. This finding suggests that successful combination of the functionalities would possibly lead to a synergy. Werbovetz et al [24] reported oryzalin (6) as the most active antiparasitic agent. It showed GI₅₀ values of 0.41 and 0.73 μM in vitro against two strains of T. brucei with a selectivity index of 40–80 thereby making it a promising lead. This compound possess both amide and sulphonamide functionality. The structures of most widely used commercial antitrypanosomal drugs are shown in Fig 1.

From the foregoing, there is need to synthesize new antitrypanosomal agents that will retain high potency of melarsoprol and other commercial antitrypanosomal agents while having an improved toxicity profile.

As a continuation of our search for lead antitrypanosomal agents, we report in this work fascinating antitrypanosomal activities of newly synthesized carboxamides from unactivated carboxylic acids bearing sulphonamide functionality. The synergy arising from the successful incorporation of carboxamide group in compounds containing sulphonamide pharmacophore is exploited in this research.

**Experimental**

**Instrumentation**

All reactions requiring inert atmosphere were carried out under nitrogen atmosphere. Drying of solvents was achieved using molecular sieve for 48 h. All reagents were purchased from
commercial suppliers, Aldrich, Merck, Fluka, Avra, SD fine and Alfa Aesar. Thin layer chromatography was carried out using silica plates purchased from Avra. The plates were visualized under UV light (popular India). FT-IR spectroscopy of the compounds were run in PerkinElmer Spectrum version 10.03.06 and the bands presented in wavenumber. Proton and carbon-13 NMR spectroscopy were run in DMSO-d$_6$ and CD$_3$OD, unless otherwise stated on either Jeol 500 MHz or 400 MHz. The chemical shifts were reported in part per million with reference to tetramethylsilane. Mass spectroscopy were carried out using micro TOF electrospray time of flight (ESI-TOF) mass spectrometer (Aerodyne Research Inc. USA), sodium formate was used as the calibrant. All experiments were carried out at Prof. Sandeep Verma’s Laboratory, department of Chemistry, Indian Institute of Technology, Kanpur. Melting points were determined using digital melting point apparatus (Stuart, SMP20) and were uncorrected.

**General procedure for the synthesis of substituted benzenesulphonamoyl alkanamides (7a-x)**

Sodium carbonate (Na$_2$CO$_3$, 1.590 g, 15 mmol) was added to a solution of amino acids (6a-h, 12.5 mmol) in water (15 mL) with continuous stirring until all the solutes dissolved. The solution was cooled to -5°C and an appropriate benzenesulphonyl chloride (5a-c, 15 mmol) was added in four portions over a period of 1 h. The slurry was further stirred at room temperature for 4 h. The progress of the reaction was monitored by using TLC (MeOH/DCM, 1:9). Upon completion, the mixture was acidified using 20% aqueous hydrochloric acid to pH 2. The crystals was filtered via suction and washed with pH 2.2 buffer. The pure products (7a-x) were dried over self-indicating fused silica gel in a desiccator.

2-(4-methylphenylsulphonamido) acetic acid (7a). The amino acid was glycine, yield (2.8410 g, 99.34%), appearance white needles, mp, 88.4–88.6°C, FTIR (KBr, cm$^{-1}$): 3448 (OH of COOH), 3277 (NH), 2957 (C-H aliphatic), 1730 (C = O), 1598, 1440 (C = C), 1354, 1321 (2S = O), 1185 (SO$_2$-NH), 1111, 1094 (C-N, C-O). $^1$H NMR (500 MHz, DMSO-d$_6$) δ: 7.89 (t, J = 6.3 Hz, 1H, NH), 7.64 (d, J = 8.6 Hz, 2H, ArH), 7.33 (d, J = 8.05 Hz, 2H, ArH), 3.51 (d, J = 5.7 Hz, CH$_2$), 2.34 (s, 3H, CH$_3$). $^{13}$C NMR (500 MHz, DMSO-d$_6$) δ: 170.8 (C = O), 143.1,
valine, yield (3.2849 g, 95.56%), appearance, off-white, mp, 121.9–122.20˚C, FTIR (KBr, cm

\[118.8, 118.3, 111.9, 109.4 \text{(aromatic carbons)}, 66.9, 57.1, 21.5 \text{(aliphatic carbons)}. HRMS-ESI (m/z): \]

\[1496, 1460 (\text{C} = \text{C}), 1385, 1334 (2\text{S} = \text{O}), 1185, 1161 \text{(SO}_2\text{N}) \]

was L-phenylalanine, yield (3.9848 g, 99.93%), appearance, off-white powder, mp, 135.10–

\[142.9, 138.9, 137.3, 129.7, 128.7, 126.9, 126.8, 126.0 \text{(eight aromatic carbons)}, 57.9, 38.0, 21.5 \text{(three aliphatic carbons)}. HRMS-ESI (m/z): 320.0958 (M+H)+, calculated, 320.0951.

3-(1H-indol-2-yl)-2-[(4-methylphenyl)sulphonyl]amino)propanoic acid (7c). The amino acid was L-tryptophan, yield (4.3814 g, 97.880%), appearance, yellowish liquid, FTIR (KBr, cm

\[3385, 3302 (2\text{NH}), 2921, 2858 (\text{C-H aliphatic}), 1750 (\text{C} = \text{O}), 1618, 1598, 1494, 1457, 1429 (\text{C} = \text{C}), 1321, 1291 (2\text{S} = \text{O}), 1082, 1019 (\text{C-N}, \text{C-O}). \]

\[\text{H NMR (DMSO-d}_6, 500 MHz) \delta: 9.77 \text{(d, J = 8.60 Hz, 1H, NH of indole)}, 8.07 \text{(d, J = 8.60 Hz, 1H, NH of SO}_2\text{NH}), 7.67 \text{(d, J = 8.05 Hz, 1H, ArH)}, 7.42 \text{(d, J = 8.60 Hz, 2H, ArH)}, 7.33 \text{(d, J = 8.00 Hz, 1H, ArH)}, 7.25 \text{(t, J = 8.05 Hz, 1H, ArH)}, 7.13 \text{(d, J = 8.00 Hz, 2H, ArH)}, 7.05–7.01 \text{(m, 2H, ArH)}, 6.91 \text{(m, 1H, ArH)}, 5.92 \text{(m, 1H, ArH)}, 3.84 \text{(dd, J = 7.45, 8.00 Hz, 1H, CH)}, 3.00 \text{(dd, J = 6.3, 6.90 Hz, 1H, CH}_3\text{, CH}_2\text{)}, 2.81 \text{(dd, J = 7.45, 7.45 Hz, 1H, CH}_2\text{of CH}_3\text{)}, 2.28 \text{(s, 3H, CH}_3\text{-Ar)}. \]

\[\text{C NMR (DMSO-d}_6, 500 MHz) \delta: 173.2 (\text{C} = \text{O}), 142.7, 138.5, 136.6, 129.6, 127.4, 126.8, 124.5, 121.3, 118.8, 118.3, 111.9, 109.4 \text{(aromatic carbons)}, 66.9, 57.1, 21.5 \text{(aliphatic carbons)}. HRMS-ESI (m/z): 359.1060 (M+H)+, calculated, 359.1064.

4-Methyl-2-[(4-methylphenyl)sulfonyl]amino)pentanoic acid (7d). The amino acid was L-leucine, yield (3.502 g, 98.26%), appearance, off-white powder, mp, 114.10–114.50°C. FTIR (KBr, cm

\[3423 (\text{OH of CO}_2\text{H}), 1732 (\text{C} = \text{O}), 1429, 1389, 1299, 1286, 1270, 1260 \text{(aromatic carbons)}, 54.5, 41.5, 24.4, 23.1, 21.6 \text{(aliphatic carbons)}. HRMS-ESI (m/z): 286.1986 (M+H)+, calculated, 286.1988.

3-methyl-2-[(4-methylphenyl)sulfonyl]amino)pentanoic acid (7e). The amino acid was L-isoleucine, yield (3.412 g, 95.74%), appearance, off-white, mp, 114.10–114.50°C, FTIR (KBr, cm

\[8.12 (d, J = 9.15 \text{Hz, 1H, NH}, 7.46 (d, J = 7.45 \text{Hz, 2H, ArH}), 7.42 (d, J = 8.60 \text{Hz, 2H, ArH}), 7.14 (m, 5H, ArH)}, 3.82 \text{(dd, J = 3.45, 2.85 Hz, 1H, CH)}, 2.89 \text{(dd, J = 5.75, 5.75 Hz, 1H, CH}_3\text{of CH}_2\text{)}, 2.67 \text{(dd, J = 8.6, 8.6 Hz, 1H, CH}_2\text{of CH}_3\text{)}, 2.31 \text{(m, 3H, CH}_3\text{)}. \]

\[\text{C NMR (DMSO-d}_6, 500 MHz) \delta: 172.8 \text{(C} = \text{O)}, 142.8, 138.7, 137.3, 129.7, 128.7, 126.9, 126.8, 126.0 \text{(eight aromatic carbons)}, 57.9, 38.0, 21.5 \text{(three aliphatic carbons)}. HRMS-ESI (m/z): 359.1060 (M+H)+, calculated, 359.1064.
2.31 (m, 3H, CH$_2$-Ar), 1.88 (m, 1H, CH), 0.71 (m, 6H, 2CH$_3$). $^{13}$C NMR (DMSO-$_d_6$, 500 MHz) δ: 172.7 (C = O), 142.9, 138.9, 129.8, 127.1, 126.2 (aromatic carbons), 61.7, 30.9, 21.5, 19.5, 18.4 (aliphatic carbons). HRMS-ESI (m/z): 271.0881 (M$^+$), calculated, 271.0889.

4-Hydroxy-1-tosylpyrrolidine-2-carboxylic acid (7g). The amino acid was L-hydroxyproline, yield (3.564 g, 99.86%), appearance, white needles, mp, 98.40–98.60°C. FTIR (KBr, cm$^{-1}$): 3524 (OH), 2931 (C-H aliphatic), 1708 (C = O), 1600, 1444 (C = C), 1347, 1332 (2S = O), 1200, 1158 (SO$_2$), 1090, 1075 (C-N or C-O). $^1$H NMR (DMSO-$_d_6$, 400 MHz) δ: 7.65 (d, J = 8.00 Hz, 2H, ArH), 7.37 (d, J = 8.05 Hz, 2H, ArH), 4.18 (s, 1H, O-H), 4.01 (t, J = 8.05 Hz, 1H, CH-CO$_2$H), 3.42 (m, 1H, CH-OH), 3.05 (d, J = 10.3 Hz, 2H, CH$_2$), 2.36 (s, 3H, CH$_3$), 1.91 (t, J = 4.6 Hz, 2H, CH$_2$). $^{13}$C NMR (DMSO-$_d_6$, 400 MHz) δ: 173.8 (C = O), 143.7, 135.0, 130.1, 127.9 (aromatic carbons), 68.9, 60.2, 56.8, 21.5 (aliphatic carbons). HRMS-ESI (m/z): 286.1097 (m+H)$^+$, calculated, 286.1097.

1-Tosylpyrrolidine-2-carboxylic acid (7h). The amino acid was L-proline, yield (3.2986 g, 98.90%), appearance, yellowish powder, mp, 50.4–50.80°C. FTIR (KBr, cm$^{-1}$): 3415 (OH of COOH), 2957 (C-H aliphatic), 1737 (C = O), 1619, 1597, 1494, 1449 (C = C), 1345, 1306 (2S = O), 1199 (SO$_2$), 1159, 1095, 1013 (C-N, C-O). $^1$H NMR (DMSO-$_d_6$, 500 MHz) δ: 7.65 (d, J = 8.6 Hz, 2H, ArH), 7.35 (d, J = 8.00 Hz, 2H, ArH), 4.04 (dd, J = 4.55, 5.15 Hz, 1H, CH-COOH), 3.29 (dd, J = 9.75, 5.15Hz, 1H, CH$_2$ of CH$_2$-N), 3.09 (dd, J = 6.85, 7.45 Hz, 1H, CH$_2$ of CH$_2$-N). HRMS-ESI (m/z): 269.0726. Calculated, 269.0726.

2-Benzensulphonamido acetic acid (7i). The amino acid was glycine, yield (2.6856 g, 99.61%), appearance, off-white powder, mp, 170.80–170.90°C. FTIR (KBr, cm$^{-1}$): 3317 (NH), 3060, 2974 (C-H aromatic), 2946 (C-H aliphatic), 1728 (C = O), 1587, 1451, 1428, 1412 (C = C), 1318, 1247 (S = O), 1158, 1130 (SO$_2$NH), 1095, 1077, 1012 (C-N, C-O). $^1$H NMR (DMSO-$_d_6$, 500 MHz) δ: 8.01 (t, J = 12.00 Hz, 1H, NH), 7.76 (d, J = 7.45 Hz, 2H, ArH), 7.59 (t, J = 7.45 Hz, 1H, ArH), 7.54 (t, J = 8.00 Hz, 2H, ArH), 3.55 (d, J = 6.30 Hz, 2H, CH$_2$). $^{13}$C NMR (DMSO-$_d_6$, 500 MHz) δ: 173.7 (C = O), 143.9, 135.1, 130.3, 127.6 (aromatic carbons), 66.9, 48.9, 30.9, 24.7, 21.4 (aliphatic carbons). HRMS-ESI (m/z): 271.0881 (m+H)$^+$, calculated, 269.0726.

2-Benzensulphonamido-3-phenylpropanoic acid (7j). The amino acid was L-phenylalanine, yield (3.8169 g, 100%), appearance, off-white powder, mp, 129.10–129.50°C. FTIR (KBr, cm$^{-1}$): 3342 (NH), 3195, 3029 (C-H aromatic), 2968 (C-H aliphatic), 1735 (C = O), 1697, 1496, 1447 (C = C), 1375, 1347 (2S = O), 1170, 1108 (SO$_2$NH), 1093, 1028 (C-N, C-O). $^1$H NMR (DMSO-$_d_6$, 500 MHz) δ: 8.25 (d, J = 8.85 Hz, 1H, NH), 7.52 (m, 3H, ArH), 7.40 (t, J = 7.45 Hz, 2H, ArH), 7.15 (m, 3H, ArH), 7.08 (d, J = 7.15 Hz, 2H, ArH), 3.84 (dd, J = 6.00, 5.75, 6.30 Hz, 1H, CH-CO$_2$H), 2.90 (dd, J = 5.75, 5.75 Hz, 1H, CH$_2$ of CH$_2$), 2.67 (dd, J = 9.00, 9.00 Hz, 1H, CH$_2$ of CH$_2$), 2.57 (d, J = 8.60 Hz, 2H, ArH). $^{13}$C NMR (DMSO-$_d_6$, 500 MHz) δ: 172.8 (C = O), 141.6, 137.3, 132.6, 129.7, 129.4, 128.7, 127.1, 126.7 (aromatic carbons), 57.9, 38.3 (aliphatic carbons). HRMS-ESI (m/z): 304.0624 (M–H)$^-$, calculated, 304.0628.

2-Benzensulphonamido-3-(1H-indol-3-yl)propanoic acid (7k). The amino acid was L-tryptophan, yield (4.2805 g, 99.43%), appearance, faint yellow powder, mp, 106.40–106.70°C. FTIR (KBr, cm$^{-1}$): 3366, 3311 (2NH), 3061 (C-H aromatic), 2936 (C-H aliphatic), 1746 (C = O), 1619, 1550, 1413, 1430 (C = C), 1323, 1235 (2S = O), 1214, 1160 (SO$_2$NH), 1127, 1091, 1012 (C-N, C-O). $^1$H NMR (DMSO-$_d_6$, 500 MHz) δ: 10.78 (s, 1H, NH of indole), 8.22 (d, J = 8.60 Hz, 1H, NH), 7.57 (m, 2H, ArH), 7.48 (t, J = 6.85 Hz, 1H, ArH), 7.37 (m, 2H, ArH), 7.27 (d, J = 8.60 Hz, 2H, ArH), 7.01 (m, 2H, ArH), 6.90 (t, J = 7.40 Hz, 1H, ArH), 3.89 (m, 1H, ArH), 3.03 (dd, J = 6.85, 6.85 Hz, 1H, CH$_2$ of CH$_3$), 2.83 (dd, J = 8.05, 7.45 Hz, 1H, CH$_2$ of CH$_2$). $^{13}$C NMR (DMSO-$_d_6$, 500 MHz) δ: 173.1 (C = O), 141.5, 136.6, 132.6, 129.2, 127.5,
126.7, 124.5, 121.4, 118.9, 118.4, 111.9, 109.4 (aromatic carbons), 57.2, 28.8 (aliphatic carbons).

**2-Benzylsulphonamido-4-methylpentanoic acid (7l).** The amino acid was L-leucine, yield (3.0592 g, 90.20%), appearance, off-white powder, mp, 105.60 °C. FTIR (KBr, cm⁻¹): 3248 (NH), 3068 (C-H aromatic), 2959, 2921, 2874 (C-H aliphatic), 1712 (C = O), 1632, 1469, 1450, 1428 (C = C), 1327, 1314 (2S = O), 1184, 11670 (SO₂NH), 1092, 1077 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 8.09 (d, J = 8.72 Hz, 1H, NH), 7.72 (t, J = 6.88 Hz, 2H, ArH), 7.54 (m, 3H, ArH), 3.60 (m, 1H, CH-CO₂H), 1.50 (m, 1H, CH), 1.33 (m, 2H, CH₂), 0.70 (m, 6H, CH₃).

⁰¹C NMR (DMSO-d₆, 400 MHz) δ: 173.8 (C = O), 141.6, 132.8, 129.5, 126.9, 126.1 (aromatic carbons), 54.5, 41.4, 24.4, 23.1, 21.5 (aliphatic carbons). HRMS-ESI (m/z): 272.1982 (M⁺), calculated, 272.1983.

**2-Benzylsulphonamido-3-methylpentanoic acid (7m).** The amino acid was L-isoleucine, yield (3.1052 g, 91.55%), appearance, off-white powder, mp, 148.00–148.30 °C. FTIR (KBr, cm⁻¹): 3295 (NH), 2968 (C-H aromatic), 2936, 2883 (C-H aliphatic), 1699 (C = O), 1585, 1450, 1416 (C = C), 1340, 1384 (2S = O), 1168 (SO₂NH), 1092, 1026 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 8.00 (d, J = 9.16 Hz, 1H, NH), 7.72 (d, J = 8.60 Hz, 2H, ArH), 7.54 (m, 3H, CH₂), 3.50 (dd, J = 7.45, 7.45 Hz, 1H, CH-CO₂H), 1.60 (m, 1H, CH), 1.30 (m, 1H, CH₃ of CH₂), 1.04 (m, 1H, CH₃ of CH₂), 0.71 (m, 6H, CH₃), 13C NMR (DMSO-d₆, 400 MHz) δ: 172.7 (C = O), 141.6, 132.8, 129.4, 127.0 (aromatic carbons), 60.5, 37.4, 24.9, 15.9, 11.4 (aliphatic carbons). HRMS-ESI (m/z): 271.0879 (M⁺), calculated, 271.0878.

**2-Benzylsulphonamido-3-methylbutanoic acid (7n).** The amino acid was L-valine, yield (3.2030 g, 99.68%), appearance, white needles, mp, 143.60–143.90 °C. FTIR (KBr, cm⁻¹): 3418 (OH CO₂H), 3302 (NH), 2969 (C-H aliphatic), 1703 (C = O), 1585, 1451 (C = C), 1338, 1294 (2S = O), 1169, 1143 (SO₂NH), 1093, 1042 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 7.97 (d, J = 9.16 Hz, 1H, NH), 7.73 (d, J = 6.88 Hz, 2H, ArH), 7.53 (m, 3H, ArH), 3.46 (dd, J = 6.44, 5.96 Hz, 1H, CH-CO₂H), 1.88 (m, 1H, CH), 0.75 (m, 6H, CH₃), 13C NMR (DMSO-d₆, 400 MHz) δ: 172.7 (C = O), 141.7, 132.8, 129.4, 127.0 (aromatic carbons), 61.8, 30.9, 19.5, 18.4 (aliphatic carbons). HRMS-ESI (m/z): 258.1824 (M⁺), calculated, 258.1827.

**1-(Benzenesulphonyl)-4-hydroxyproline-2-carboxylic acid (7o).** The amino acid was L-4-hydroxyproline, yield (3.2035 g, 99.99%), appearance, white powder, mp, 159.00 °C. FTIR (KBr, cm⁻¹): 3402 (OH), 2993, 2955 (C-H aliphatic), 1714 (C = O), 1589, 1484, 1450 (C = C), 1385, 1353 (2S = O), 1195, 1158 (SO₂NH), 1158, 1100, 1070 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 7.77 (d, J = 7.32 Hz, 2H, ArH), 7.63 (t, J = 7.36 Hz, 1H, ArH), 7.56 (t, J = 7.80 Hz, 2H, ArH), 4.18 (s, 1H, OH), 4.04 (t, J = 7.80 Hz, 1H, CH-CO₂H), 3.43 (m, 1H, CHOH), 3.09 (d, J = 11.00 Hz, 2H, CH₂-N), 1.92 (m, 2H, CH₂). ¹³C NMR (DMSO-d₆, 400 MHz) δ: 173.8 (C = O), 137.8, 133.5, 129.6, 127.9 (aromatic carbons), 68.9, 60.2, 56.8, 31.2 (aliphatic carbons). HRMS-ESI (m/z): 271.0518 (M⁺), calculated, 271.0514.

**1-(Benzenesulphonyl)-pyrrolidine-2-carboxylic acid (7p).** The amino acid was L-proline, yield (3.1911 g, 100%), appearance, yellowish oil. FTIR (KBr, cm⁻¹): 3066 (C-H aromatic), 2983, 2884 (C-H aliphatic), 1730 (C = O), 1627, 1447 (C = C), 1343, 1292 (2S = O), 1199, 1161 (SO₂NH), 1095, 1073, 1016 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 7.80 (m, 2H, ArH), 7.65 (m, 1H, ArH), 7.58 (m, 2H, ArH), 4.07 (dd, J = 4.60, 4.60 Hz, 1H, CH-CO₂H), 3.31 (m, 1H, CH₃ of CH₂N), 3.11 (m, 1H, CH₃ of CH₂N), 1.78 (m, 3H), 1.50 (m, 1H). ¹³C NMR (DMSO-d₆, 400 MHz) δ: 173.7 (C = O), 137.8, 133.6, 129.9, 127.6 (aromatic carbons), 60.9 48.9, 30.9, 24.7 (aliphatic carbons). HRMS-ESI (m/z): 256.1679 (M⁺), calculated 256.1680.

**2-(4-Nitrobenzylsulphonamido)acetic acid (7q).** The amino acid was glycine, yield (2.2152 g, 94.59%), appearance, off-white powder, mp, 171.9–172.30 °C. FTIR (KBr, cm⁻¹): 3417 (OH of CO₂H), 3297 (NH), 3108, 3070 (C-H aromatic), 1732 (C = O), 1605, 1482 (C = C), 1529, 1424 (N-O), 1354, 1333 (2S = O), 1240, 1165 (SO₂NH), 1100, 1087, 1014 (C-N,
Synthesis of new anti-trypanosomal agents

2-(4-Nitrophosphonamido)-3-phenylpropanoic acid (7r). The amino acid was L-phenylalanine, yield (3.1530 g, 99.99%), appearance, white powder, mp, 100.10–100.40˚C. FTIR (KBr, cm⁻¹): 3417 (OH of CO₂H), 3253 (NH), 3182, 3111 (C-H aromatic), 1753 (C = O), 1607, 1456, 1435 (C = C), 1525, 1403 (N-O), 1348, 1332 (2S = O), 1167, 1119 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 10.66 (s, 1H, NH, indole), 8.60 (d, J = 8.6 Hz, 1H, NH), 7.85 (m, 2H, ArH), 7.48 (m, 2H, ArH), 7.23 (d, J = 7.45 Hz, 1H, ArH), 7.04 (d, J = 8.00 Hz, 1H, ArH), 6.99 (s, 1H, ArH), 6.85 (m, 2H, ArH), 3.89 (ddd, J = 4.6 Hz, 4.6 Hz, 4.6 Hz, 1H, CH of CH₃), 2.97 (dd, J = 9.75 Hz, 1H, CH₃ of CH₂). ¹³C NMR (DMSO-d₆, 400 MHz) δ: 173.3 (C = O), 148.9, 146.4, 136.5, 127.4, 126.9, 124.9, 123.8, 121.2, 118.8, 118.2, 111.7, 109.2 (aromatic carbons), 57.0, 28.4 (aliphatic carbons). HRMS-ESI (m/z): 390.0126 (M+H)⁺, calculated 390.0124.

4-Methyl-2-nitrophosphonamido)pentanoic acid (7t). The amino acid was L-leucine, yield (2.8461 g, 99.98%), appearance, white powder, mp, 142.90–143.20˚C. FTIR (KBr, cm⁻¹): 3272 (NH), 3113, 3097, 3074 (C-H aromatic), 2934, 2873 (C-H aliphatic), 1714 (C = O), 1658, 1606, 1469 (C = C), 1531, 1417 (N-O), 1356, 1307 (2S = O), 1168, 1156 (SO₂NH), 1108, 1091, 1010 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 8.54 (d, J = 9.15 Hz, 1H, NH), 8.35 (d, J = 8.6 Hz, 2H, ArH), 7.98 (d, J = 8.6 Hz, 2H, ArH), 3.68 (m, 1H, CH-CO₂H), 1.56 (m, 1H, CH(CH₃)₂), 1.38 (m, 2H, CH₂), 0.76 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400 MHz) δ: 173.4 (C = O), 149.9, 147.3, 128.7, 124.9 (aromatic carbons), 54.7, 41.2, 24.5, 23.1, 21.4 (aliphatic carbons). HRMS-ESI (m/z): 315.1265 (M+H)⁺, calculated 315.1266.

3-Methyl-2-(4-nitrophosphonamido)pentanoic acid (7u). The amino acid was L-isoleucine, yield (2.7894 g, 97.97%), appearance, white powder, mp, 131.40–131.70˚C. FTIR (KBr, cm⁻¹): 3271 (NH), 3182, 3111 (C-H aromatic), 2934, 2873 (C-H aliphatic), 1714 (C = O), 1658, 1606, 1469 (C = C), 1531, 1417 (N-O), 1356, 1307 (2S = O), 1168, 1156 (SO₂NH), 1108, 1091, 1010 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 8.82 (d, J = 9.15 Hz, 1H, NH), 8.35 (d, J = 8.6 Hz, 2H, ArH), 7.99 (d, J = 8.55 Hz, 2H, ArH), 3.61 (t, J = 6.00 Hz, 1H, CH-CO₂H), 1.67 (m, 1H, CH), 1.32 (m, 1H, CH₃ of CH₂), 1.07 (m, 1H, CH₃ of CH₂), 0.75 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400 MHz) δ: 172.4 (C = O), 149.9, 147.2, 128.7, 124.8 (aromatic carbons), 60.9, 37.3, 24.9, 15.9, 11.5 (aliphatic carbons). HRMS-ESI (m/z): 317.2387 (M+H)⁺, calculated 317.2386.

3-Methyl-2-(4-nitrophosphonamido)butanoic acid (7v). The amino acid was L-valine, yield (2.7200 g, 99.97%), appearance, white needles, mp, 182.60–182.90˚C. FTIR (KBr, cm⁻¹): 3415 (OH of CO₂H), 3278 (NH), 3113, 2969 (C-H aromatic), 2931, 2873 (C-H aliphatic), 1711 (C = O), 1638, 1607, 1411 (C = C), 1532, 1463 (N-O), 1356, 1312 (2S = O), 1169, 1146 (SO₂NH), 1107, 1091, 1062, 1013 (C-N, C-O). ¹H NMR (DMSO-d₆, 400 MHz) δ: 8.4367–
8.4184 (d, J = 9.15 Hz, 1H, NH), 8.3577–8.3405 (d, J = 8.6 Hz, 1H, CH=CO₂H), 1.9756–1.9091 (m, 1H, CH₂(CH₃)), 0.8063–0.7559 (m, 6H, 2CH₃).

13C NMR (DMSO-d₆, 400 MHz) δ: 172.4 (C = O), 149.9, 147.3, 128.7, 124.8 (aromatic carbons), 61.9, 30.8, 19.6, 18.3 (aliphatic carbons).

HRMS-ESI (m/z): 320.0579 (M+NH₄)⁺, calculated, 320.0573.

4-Hydroxy-1-(4-nitrophenylsulphonyl)pyrroline-2-carboxylic acid (7w).
The amino acid was L-hydroxyproline, yield (2.8459 g, 99.97%), appearance, white needles, mp, 199.8–200.20°C. FTIR (KBr, cm⁻¹): 3491 (OH), 3416 (OH of CO₂H), 3117, 3024 (C-H aromatic), 2966, 2767 (C-H aliphatic), 1750 (C = O), 1638, 1608, 1457 (C = C), 1527, 1427 (N-O), 1359, 1331 (2S = O), 1184, 1164 (SO₂N), 1136, 1112, 1090, 1015, 1005 (C-N, C-O).

1H NMR (DMSO-d₆, 500 MHz) δ: 8.36 (d, J = 9.15 Hz, 2H, ArH), 8.03 (d, J = 8.60 Hz, 2H, ArH), 4.17 (s, 1H, OH), 4.11 (t, J = 8.6 Hz, 1H, CH-CO₂H), 3.45 (dd, J = 3.45, 3.40 Hz, 1H, CHOH), 3.20 (d, J = 10.90 Hz, 2H, CH₂N), 2.02 (m, 1H, CHa, CH₂), 1.91 (m, 1H, CHb of CH₂).

13C NMR (DMSO-d₆, 500 MHz) δ: 173.5, 150.3, 143.6, 129.5, 124.9 (aromatic carbons), 69.0, 60.4, 57.1 (aliphatic carbons). HRMS-ESI (m/z): 303.2987 (M+H)⁺, calculated 303.2984.

1-(4-Nitrophenylsulphonyl)pyrroline-2-carboxylic acid (7x).
The amino acid was L-proline, yield (2.6051 g, 96.39%), appearance, off-white needles, mp, 149.90–150.20°C. FTIR (KBr, cm⁻¹): 3415 (OH of CO₂H), 3111 (C-H aromatic), 2899, 2648 (C-H aliphatic), 1723 (C = O), 1641, 1604, (C = CO₂H), 1533, 1447 (N-O), 1353, 1305 (2S = O), 1199, 1165 (SO₂N), 1072, 1024, 1008 (C-N, C-O).

1H NMR (DMSO-d₆, 500 MHz) δ: 8.38 (m, 2H, ArH), 8.06 (m, 2H, ArH), 4.18 (m, 1H, CH-CO₂H), 3.37 (m, 1H, CHa of CH₂), 3.20 (m, 1H, CHb of CH₂), 1.96 (m, 1H, CHa of CH₂), 1.81 (m, 2H, CH₂), 1.63 (m, 1H, CH). 13C NMR (DMSO-d₆, 500 MHz) δ: 173.4 (C = O), 150.4, 143.6, 129.5, 124.9 (aromatic carbons), 69.1, 48.9, 30.9, 24.7 (aliphatic carbons). HRMS-ESI (m/z): 301.0144 (M+H)⁺, calculated, 301.0143.

General procedure for the synthesis of N-benzoyl derivatives of benzenesulphonamides (9a-f, i-n and q-v)
Appropriate benzenesulphonamides (7a-f, i-n and q-v, 1.0 mmol) was dissolved in NaOH (10%, 10 mL) in a 50 mL round bottom flask and benzoyl chloride (8, 1.1 mmol, 0.2 mL) was added into the solution and stirred at room temperature. The reaction progress was monitored by TLC (3% MeOH/DCM) to the disappearance of the benzenesulphonamide spot. Upon completion, the solution was transferred into a beaker containing crushed ice and then acidified to pH 3 with concentrated hydrochloric acid. The solid was collected via suction filtration and transferred into a beaker containing CCl₄ (10 mL) and covered with watch glass boiled for 10 min. The mixture was allowed to cool slightly and then filtered. The products (9a-f, i-n and q-v) obtained were washed with 10–20 mL CCl₄ and dried over fused self-indicating silica gel in a desiccator.

{Benzoyl[(4-methylphenyl)sulfonyl]amino}acetic acid (9a). Yield (0.3281 g, 98.49%), appearance, white powder, mp, 104.60–104.80°C. FTIR (KBr, cm⁻¹): 3072 (C-H aromatic), 1729, 1687 (2C = O), 1641, 1504, 1477 (N-O), 1353, 1305 (2S = O), 1199, 1165 (SO₂N), 1072, 1024, 1008 (C-N, C-O). 1H NMR (DMSO-d₆, 500 MHz) δ: 8.36 (d, J = 8.6 Hz, 2H, ArH), 8.06 (m, 2H, ArH), 4.18 (m, 1H, CH-CO₂H), 3.37 (m, 1H, CHa of CH₂), 3.20 (m, 1H, CHb of CH₂), 1.96 (m, 1H, CHa of CH₂), 1.81 (m, 2H, CH₂), 1.63 (m, 1H, CH). 13C NMR (DMSO-d₆, 500 MHz) δ: 170.8, 167.8 (2C = O), 143.1, 138.4, 133.4, 131.3, 130.0, 129.8, 129.1, 127.1 (aromatic carbons), 44.3, 21.5 (aliphatic carbons). HRMS-ESI (m/z): 333.0679 (M+H)⁺, calculated, 333.0671.

2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-3-phenylpropanoic acid (9b). Yield (0.4201 g, 98.39%), appearance, white powder, mp, 100.50–100.70°C. FTIR (KBr, cm⁻¹): 3443 (OH of CO₂H), 3072 (C-H aromatic), 1732, 1689 (2C = O), 1603, 1585, 1497, 1454, 1425.
3-(1H-indol-2-yl)-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]propanoic acid (9c). Yield (0.4609 g, 99.74%), appearance, white powder, mp, 108.60–109.00°C, FTIR (KBr, cm⁻¹): 3335 (NH), 3072 (C-H aromatic), 1761, 1688 (2C = O), 1619, 1602, 1584, 1454, 1424 (C = C), 1326, 1292 (2S = O), 1178, 1160 (SO₂N), 1128, 1073, 1027 (C-N, C-O). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.91 (m, 1H, NH of indole), 7.91 (t, J = 7.45 Hz, 3H, ArH), 7.58 (t, J = 7.45 Hz, 2H, ArH), 7.45 (m, 5H, ArH), 7.25 (t, J = 8.60 Hz, 1H, ArH), 7.13 (d, J = 8.05 Hz, 1H, ArH), 7.01 (t, J = 7.45 Hz, 1H, ArH), 6.18 (t, J = 7.45 Hz, 1H, ArH), 3.84 (dd, J = 7.45, 8.05 Hz, 1H, ArH), 3.01 (dd, J = 6.30, 6.30 Hz, 1H, CH₂ of CH₃), 2.80 (dd, J = 8.05, 8.00 Hz, 1H, CH₂ of CH₃), 2.28 (s, 3H, CH₃-Ar). ¹³C NMR (DMSO-d₆, 500MHz) δ: 172.8, 167.8 (2C = O), 142.7, 138.5, 136.6, 133.4, 131.3, 129.8, 129.7, 129.1, 127.4, 126.8, 124.5, 121.3, 118.8, 118.3, 111.9, 109.4 (aromatic carbons), 57.1, 28.8, 21.5 (aliphatic carbons). HRMS-ESI (m/z): 424.1142 (M+H), calculated, 424.1140.

4-Methyl-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]pentanoic acid (9d). Yield (0.3889 g, 99.92%), appearance, white powder, mp, 98.90–99.60°C, FTIR (KBr, cm⁻¹): 3415 (OH of CO₂H), 2968 (C-H aromatic), 2676 (C-H aliphatic), 1705, 1688 (2C = O), 1619, 1602, 1584, 1454, 1424 (C = C), 1326, 1292 (2S = O), 1161, 1128 (SO₂N), 1091, 1073, 1027 (C-N, C-O). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.91 (t, J = 6.90 Hz, 3H, ArH), 7.59 (m, 2H, ArH), 7.46 (t, J = 8.00 Hz, 3H, ArH), 7.31 (d, J = 8.00 Hz, 1H, ArH), 3.59 (dd, J = 8.05, 8.55 Hz, 1H, CH=CO₂H), 1.52 (m, 1H, CH), 1.33 (m, 2H, CH₂), 0.76 (d, J = 6.30 Hz, 3H, CH₃), 0.65 (d, J = 6.30 Hz, 3H, CH₃). ¹³C NMR (DMSO-d₆, 500MHz) δ: 173.2, 167.8 (2C = O), 142.9, 138.9, 133.4, 131.3, 129.9, 129.8, 129.1, 127.0 (aromatic carbons), 54.5, 41.5, 24.4, 23.1, 21.6, 21.5 (aliphatic carbons). HRMS-ESI (m/z): 390.2354 (M+NH₄⁺), calculated, 390.2358.

3-Methyl-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]pentanoic acid (9e). Yield (0.3890 g, 99.95%), mp, 98.40–99.90°C, FTIR (KBr, cm⁻¹): 3415 (OH of CO₂H), 2970 (C-H of aromatic), 1707, 1688 (2C = O), 1602, 1584, 1496, 1442 (C = C), 1328, 1292 (2S = O), 1186, 1161 (SO₂N), 1128, 1073, 1027 (C-N, C-O). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.89 (m, 3H, ArH), 7.59 (m, 2H, ArH), 7.46 (t, J = 8.00 Hz, 3H, ArH), 7.30 (d, J = 8.00 Hz, 1H, ArH), 3.49 (d, J = 2.3 Hz, 1H, CH=CO₂H), 2.33 (s, 3H, CH₃-Ar), 1.61 (m, 1H, CH), 1.31 (m, 1H, CH₂ of CH₃), 1.05 (m, 1H, CH₃ of CH₂), 0.72 (dt, J = 6.30, 6.90 Hz, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 500MHz) δ: 172.7, 167.8 (2C = O), 142.9, 138.9, 133.4, 131.3, 129.8, 129.4, 129.1, 127.1 (aromatic carbons), 60.5, 37.5, 24.9, 21.5, 15.9, 11.4 (aliphatic carbons). HRMS-ESI (m/z): 388.0894 (M-H), calculated, 388.0896.

3-Methyl-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]butanoic acid (9f). Yield (0.372 g, 99.20%), appearance, white powder, mp, 99.90–100.20°C, FTIR (KBr, cm⁻¹): 3415 (OH, CO₂H), 2970 (C-H aliphatic), 1706, 1688 (2C = O), 1618, 1602, 1584, 1454, 1424 (C = C), 1328, 1292 (2S = O), 1185, 1161 (SO₂N), 1127, 1087, 1073 (C-N, C-O). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.91 (d, J = 7.45 Hz, 2H, ArH), 7.59 (m, 4H, ArH), 7.45 (t, J = 8.00 Hz, 2H, ArH), 7.30 (d, J = 8.00 Hz), 3.45 (d, J = 4.60 Hz, 1H, CH- CO₂H), 1.88 (m, 1H, CH), 0.77 (m, 6H, CH₃). ¹³C NMR (DMSO-d₆, 500MHz) δ: 172.7, 167.9 (2C = O), 142.9, 138.9, 133.4, 131.3, 129.8, 129.3, 129.1, 127.1 (aromatic carbons), 61.7, 30.9, 21.5, 19.5, 18.4 (aliphatic carbons). HRMS-ESI (m/z): 375.1148 (M⁺), calculated, 375.1140.
2-[N-(benzenesulfonyl)-1-phenylformamido]acetic acid (9i). Yield (0.2999 g, 93.92%), appearance, white needles, mp, 121.60–121.90 °C, FTIR (KBr, cm⁻¹): 3073, 3011 (C-H aliphatic), 2937 (C-H aromatic), 1732, 1688 (2C = O), 1619, 1603, 1584, 1454, 1425 (C = C), 1327, 1292 (2S = O), 1186, 1128 (SO₂N), 1101, 1073, 1027 (C-N, C-O). ¹H NMR (DMSO-d₆, 400MHz) δ: 7.90 (t, J = 8.20 Hz, 4H, ArH), 7.57 (m, 2H, ArH), 7.45 (t, J = 7.80 Hz, 4H, ArH), 3.54 (s, 2H, CH₂). ¹³C NMR (DMSO-d₆, 400MHz) δ: 174.7, 167.9 (2C = O) 154.1, 151.1, 133.4, 131.3, 129.8, 129.1, 119.4, 112.8 (eight aromatic carbons), 59.0 (aliphatic carbon). HRMS-ESI (m/z): 320.0516 (M+H), calculated, 320.0514.

2-[N-(benzenesulfonyl)-1-phenylformamido]-3-phenylpropanoic acid (9j). Yield (0.4090 g, 99.90%), appearance, white powder, mp, 94.10–94.70 °C, FTIR (KBr, cm⁻¹): 3342 (OH of COOH), 3073, 3029 (C-H aromatic), 2968 (C-H aliphatic), 1735, 1688 (C = O), 1603, 1584, 1496, 1453, 1425 (C = C), 1376, 1348 (2S = O), 1170, 1108 (SO₂N), 1094, 1073, 1027, 1000 (C-N, C-O). ¹H NMR (DMSO-d₆, 400MHz) δ: 7.91 (d, J = 8.00 Hz, 4H, ArH), 7.58 (t, J = 7.45 Hz, 2H, ArH), 7.52 (t, J = 8.00 Hz, 1H, ArH), 7.45 (m, 4H, ArH), 7.39 (t, J = 8.00 Hz, 1H, ArH), 7.15 (m, 2H, ArH), 7.08 (d, J = 6.30 Hz, 1H, ArH), 3.84 (t, J = 5.75 Hz, 1H, CH-COOH), 2.90 (dd, J = 5.70, 5.70 Hz, 1H, CH₂ of CH₃), 2.67 (dd, J = 9.15, 9.15 Hz, 1H, CH₃ of CH₂). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.8, 167.8 (2C = O), 141.5, 137.3, 133.4, 132.6, 131.3, 129.8, 129.7, 129.4, 129.1, 128.7, 127.1, 126.8 (twelve aromatic carbons), 57.9, 38.3 (aliphatic carbons). HRMS-ESI (m/z): 410.0988 (M+H), calculated, 410.0983.

2-[N-(benzenesulfonyl)-1-phenylformamido]-3-(1H-indol-2-yl)propanoic acid (9k). Yield (0.4480 g, 99.89%), appearance, white powder, mp, 110.90–111.20 °C, FTIR (KBr, cm⁻¹): 3385 (OH of COOH), 3305 (NH of indole), 3072 (C-H of aromatic), 2839 (C-H aliphatic), 1747, 1687 (2C = O), 1602, 1584, 1454, 1425 (C = C), 1339, 1292 (2S = O), 1162, 1129 (SO₂N), 1083, 1027 (C-O, C-N). ¹H NMR (DMSO-d₆, 500MHz) δ: 10.79 (s, 1H, NH), 7.91 (m, 3H, ArH), 7.57 (m, 2H, ArH), 7.46 (m, 3H, ArH), 7.35 (t, J = 7.45 Hz, 2H, ArH), 7.26 (m, 2H, ArH), 7.01 (t, J = 6.85 Hz, 2H, ArH), 6.90 (t, J = 7.45 Hz, 1H, ArH), 3.87 (dd, J = 7.45, 8.05 Hz, 1H, CH-COOH), 3.02 (dd, J = 6.85, 6.30 Hz, 1H, CH₃ of CH₂), 2.82 (dd, J = 7.45, 7.45 Hz, 1H, CH₃ of CH₂). ¹³C NMR (DMSO-d₆, 500MHz) δ: 173.1, 167.9 (2C = O), 141.4, 136.6, 133.4, 132.6, 131.3, 129.8, 129.2, 129.1, 127.5, 126.7, 124.5, 121.4, 118.9, 118.4, 111.9, 109.4 (sixteen aromatic carbons), 57.2, 28.8 (aromatic carbons). HRMS-ESI (m/z): 449.1096 (M+H), calculated, 449.1093.

2-[N-(benzenesulfonyl)-1-phenylformamido]-4-methylpentanoic acid (9l). Yield (0.3659 g, 97.86%), appearance, white powder, mp, 90.40–90.60 °C, FTIR (KBr, cm⁻¹): 3072 (C-H aromatic), 2959, 2874, 2838 (C-H aliphatic), 1721, 1687 (2C = O), 1603, 1584, 1454, 1426 (C = C), 1327, 1292 (2S = O), 1186, 1128 (SO₂N), 1093, 1074, 1027 (C-N, C-O). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.91 (t, J = 8.60 Hz, 3H, ArH), 7.74 (d, J = 7.45 Hz, 1H, ArH), 7.58 (m, 2H, ArH), 7.52 (t, J = 8.05 Hz, ArH), 7.46 (t, J = 8.00 Hz, 3H, ArH), 3.61 (m, 1H, CH-COOH), 1.49 (m, 1H, CH), 1.34 (m, 2H, CH₂), 0.72 (m, 6H, CH₃), ¹³C NMR (DMSO-d₆, 400MHz) δ: 173.8, 167.9 (2C = O), 141.6, 133.4, 132.8, 131.3, 129.8, 129.5, 129.1, 126.9 (eight aromatic carbons), 54.5, 41.4, 24.3, 23.1, 21.5 (five aliphatic carbons). HRMS-ESI (m/z): 376.1143 (M+H), calculated, 376.1140.

2-[N-(benzenesulfonyl)-1-phenylformamido]-3-methylpentanoic acid (9m). Yield (0.3750 g, 99.89%), appearance, white powder, mp, 91.40–91.90 °C, FTIR (KBr, cm⁻¹): 3295 (OH of COOH), 3072 (C-H aromatic), 2969, 2883 (C-H aliphatic), 1723, 1698 (C = O), 1619, 1603, 1584, 1454, 1425 (C = C), 1327, 1292 (2S = O), 1169, 1129 (SO₂N), 1092, 1074, 1027 (C-N, C-O). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.89 (d, J = 7.15 Hz, 2H, ArH), 7.72 (d, J = 7.15 Hz, 1H, ArH), 7.55 (m, 2H, ArH), 7.47 (m, 5H, ArH), 3.50 (t, J = 6.30 Hz, 1H, CH-COOH), 1.59 (m, 1H, CH), 1.28 (m, 1H, CH₃ of CH₂), 1.03 (m, 1H, CH₃ of CH₂), 0.72 (d, J = 6.90 Hz, 3H, CH₃ of CH₂), 0.67 (t, J = 7.45 Hz, 3H, CH₃ of CH₂). ¹³C NMR (DMSO-d₆, 500MHz) δ: 172.7, 167.9.
(2C = O), 141.5, 133.4, 132.8, 131.2, 129.8, 129.4, 129.1, 126.9 (eight aromatic carbons), 60.6, 37.4, 24.9, 15.8, 11.3 (five aliphatic carbons). HRMS-ESI (m/z): 376.1141 (M+H), calculated, 376.1140.

2-[(benzenesulfonyl)-1-phenylformamido]-3-methylpentanoic acid (9n). Yield (0.3050 g, 84.37%), appearance, white powder, mp, 104.60–104.90˚C, FTIR (KBr, cm⁻¹): 3302 (OH of COOH), 3073, 2970 (C-H aromatic), 2877 (C-H aliphatic), 1734, 1688 (2C = O), 1603, 1584, 1454, 1425 (C = C), 1327, 1293 (2S = O), 1169, 1129 (SO₂N), 1128, 1093, 1074 (C-O, C-N). ¹H NMR (DMSO-d₆, 500MHz) δ: 7.91 (m, 3H, ArH), 7.74 (t, J = 7.45 Hz, 1H, ArH), 7.57 (m, 2H, ArH), 7.51 (d, J = 7.45 Hz, 1H, ArH), 7.46 (m, 3H, ArH), 3.49 (d, J = 6.30 Hz, 1H, CH-COOH), 1.88 (m, 1H, CH), 0.75 (m, 6H, 2CH₃).

¹³C NMR (DMSO-d₆, 500MHz) δ: 172.7, 167.9 (2C = O), 141.7, 133.4, 132.8, 131.3, 129.8, 129.4, 129.1, 127.0 (eight aromatic carbons), 61.8, 30.9, 19.5, 18.4 (aliphatic carbons). HRMS-ESI (m/z): 360.0984 (M-H), calculated, 360.0983.

2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]acetic acid (9q). Yield (0.2126 g, 58.36%), appearance, white powder, mp, 135.00–135.60˚C, FTIR (KBr, cm⁻¹): 3310 (OH of COOH), 3073, 3009 (C-H aromatic), 2839 (C-H aliphatic), 1703, 1688 (2C = O), 1604, 1584, 1422 (C = C), 1527, 1474 (N-O), 1327, 1290 (2S = O), 1183, 1166 (SO₂N), 1128, 1096, 1074 (C-N, C-O).

¹H NMR (DMSO-d₆, 500MHz) δ: 8.36 (d, 8.60 Hz, 2H, ArH), 8.01 (d, J = 8.60 Hz, 2H, ArH), 7.91 (d, J = 6.85 Hz, 2H, ArH), 7.58 (t, J = 7.45 Hz, 1H, ArH), 7.47 (t, J = 8.05 Hz, 2H, ArH), 3.67 (s, 2H, CH₂).

¹³C NMR (DMSO-d₆, 500MHz) δ: 170.7, 167.9 (2C = O), 150.0, 147.1, 133.4, 131.3, 129.8, 129.1, 128.7, 124.9 (aromatic carbons), 56.3 (CH₂). HRMS-ESI (m/z): 363.0254 (M-H), calculated, 363.0251.

2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]-3-phenylpropanoic acid (9r). Yield (0.4545 g, 100%), appearance, white powder, mp, 122.50–122.90˚C, FTIR (KBr, cm⁻¹): 3309 (OH of COOH), 3113, 3073, 3008 (C-H aromatic), 2840 (C-H aliphatic), 1703, 1685 (2C = O), 1604, 1584, 1422 (C = C), 1527, 1474 (N-O), 1327, 1290 (2S = O), 1183, 1166 (SO₂N), 1128, 1096, 1074 (C-N, C-O).

¹H NMR (DMSO-d₆, 400MHz) δ: 8.16 (m, 2H, ArH), 7.90 (t, J = 7.36 Hz, 2H, ArH), 7.70 (m, 2H, ArH), 7.59 (m, 1H, ArH), 7.46 (m, 2H, ArH), 7.07 (m, 5H, ArH), 3.92 (m, 1H, CH-CO₂H), 2.95 (dd, J = 4.60, 4.56 Hz, 1H, CHa of CH₂), 2.65 (dd, J = 10.08, 10.08 Hz, 1H, CHb of CH₂).

¹³C NMR (DMSO-d₆, 400MHz) δ: 172.7, 167.9 (2C = O), 149.6, 147.1, 137.2, 133.4, 131.3, 129.8, 129.7, 128.6, 128.2, 126.9, 124.7 (twelve aromatic carbons), 58.2, 38.1 (two aliphatic carbons). HRMS-ESI (m/z): 455.1936 (M+H), calculated, 455.1932.

3-(1H-indol-2-yl)-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]propionic acid (9s). Yield (0.4932 g, 99.64%), appearance, white powder, mp, 153.30–153.70˚C, FTIR (KBr, cm⁻¹): 3448 (OH of COOH), 3113, 3073, 3008 (C-H aromatic), 2840 (C-H aliphatic), 1703, 1685 (2C = O), 1604, 1584, 1454, 1421 (C = C), 1527 (N-O), 1327, 1289 (2S = O), 1183, 1166 (SO₂N), 1128, 1096, 1074 (C-N, C-O).

¹H NMR (DMSO-d₆, 400MHz) δ: 10.68 (s, 1H, NH of indole), 7.91 (m, 3H, ArH), 7.84 (m, 1H, ArH), 7.58 (m, 2H, ArH), 7.46 (m, 3H, ArH), 7.22 (d, J = 7.80 Hz, 1H, ArH), 7.03 (d, J = 7.80 Hz, 1H, ArH), 6.98 (d, J = 2.32 Hz, 1H, ArH), 6.84 (m, 2H, ArH), 3.88 (m, 1H, CH-COOH), 3.03 (dd, J = 4.12, 4.12 Hz, 1H, CHa of CH₂), 2.77 (dd, J = 10.08, 10.56 Hz, 1H, CHb of CH₂).

¹³C NMR (DMSO-d₆, 400MHz) δ: 173.3, 167.8 (2C = O), 148.9, 144.7, 138.9, 136.5, 133.4, 132.9, 131.3, 129.8, 129.7, 129.1, 128.6, 128.2, 126.9, 124.7 (sixteen aromatic carbons), 46.4, 36.8 (two aliphatic carbons). HRMS-ESI (m/z): 494.1936 (M+H), calculated, 494.1932.

3-Methyl-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]pentanoic acid (9t). Yield (0.4201 g, 99.93%), appearance, white powder, mp, 110.40–110.60˚C, FTIR (KBr, cm⁻¹): 3293 (OH of COOH), 3117, 3072 (C-H aromatic), 2968, 2882 (C-H aliphatic), 1730, 1691 (2C = O), 1619, 1604, 1454, 1410 (C = C), 1531 (N-O), 1349, 1310 (2S = O), 1182, 1129.
(SO₂N), 1105, 1073, 1027, 1012 (C-N, C-O). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.34 (d, J = 8.68 Hz, 2H, ArH), 7.98 (d, J = 8.72 Hz, 2H, ArH), 7.90 (t, J = 7.32 Hz, 2H, ArH), 7.57 (t, J = 7.32 Hz, 1H, ArH), 7.46 (t, J = 7.72 Hz, 2H, ArH), 3.60 (d, J = 2.28 Hz, CH-COOH), 1.67 (m, 1H, CH), 1.31 (m, 1H, CH₃ of CH₂), 1.12 (m, 1H, CH₃ of CH₂), 0.74 (m, 6H, 2CH₃).

¹³C NMR (DMSO-d₆, 400MHz) δ: 172.4, 167.8 (2C = O), 149.9, 147.2, 133.4, 131.3, 129.8, 129.1, 128.7, 124.8 (eight aromatic carbons) 60.9, 37.3, 24.8, 15.9, 11.5 (five aliphatic carbons). HRMS-ESI (m/z): 420.0995 (M⁺), calculated, 420.0991.

4-Methyl-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]pentanoic acid (9u).
Yield (0.4204 g, 100%), appearance, white powder, mp, 116.30–116.60°C, FTIR (KBr, cm⁻¹): 3412 (OH of COOH), 2960 (C-H aliphatic), 1721, 1689 (2C = O), 1603, 1584, 1454, 1410 (C = C), 1531 (N-O), 1348, 1323 (2S = O), 1177, 1149 (SO₂N), 1126, 1091, 1074, 1026 (C-N, C-O). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.35 (d, J = 8.72 Hz, 2H, ArH), 7.97 (d, J = 9.16 Hz, 2H, ArH), 7.90 (t, J = 6.88 Hz, 1H, ArH), 3.73 (t, J = 5.48 Hz, 1H, CH-COOH), 1.55 (m, 1H, CH), 0.79 (d, J = 6.44 Hz, 3H, CH₃), 0.70 (d, J = 6.40 Hz, 3H, CH₃).

¹³C NMR (DMSO-d₆, 400MHz) δ: 173.4, 167.9 (2C = O), 149.9, 147.3, 133.4, 131.3, 129.8, 129.1, 128.7, 124.9 (eight aromatic carbons), 54.7, 41.2, 24.4, 23.1, 21.4 (five aliphatic carbons). HRMS-ESI (m/z): 420.0999 (M⁺), calculated, 420.0991.

3-Methyl-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]butanoic acid (9v).
Yield (0.4063 g, 99.98%), appearance, white powder, mp, 116.10–117.20°C, FTIR (KBr, cm⁻¹): 3277 (OH of COOH), 3112, 3073 (C-H aromatic), 2969, 2874 (C-H aliphatic), 1710, 1687 (2C = O), 1606, 1584, 1454, 1424 (C = C), 1532 (N-O), 1356, 1327 (2S = O), 1169, 1146 (SO₂N), 1129, 1091, 1074, 1063, 1027, 1000 (C-N, C-O). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.34 (d, J = 9.16 Hz, 2H, ArH), 7.95 (d, J = 8.72 Hz, 2H, ArH), 7.58 (t, J = 6.88 Hz, 1H, ArH), 7.45 (m, 2H, ArH), 3.57 (s, 2H, CH₂), 2.28 (m, 3H, CH₃).

¹³C NMR (DMSO-d₆, 500MHz) δ: 172.4, 167.9 (2C = O), 149.9, 147.3, 133.4, 131.3, 129.8, 129.1, 128.7, 124.9 (eight aromatic carbons), 61.9, 30.8, 19.6, 18.3 (four aliphatic carbons). HRMS-ESI (m/z): 405.0732 (M-H), calculated, 405.0731.

Boric acid catalysed direct amidation of unactivated carboxylic acid and 3-aminoquinoline
To a suspension of N-benzoyl-substituted-benzenesulphonamides (9a-f, i-n, q-v, 7g-h, o-p and w-x) (1.0 mmol) (1.0 mmol) in dry toluene (40 mL) equipped with Dean-Stark apparatus for azeotropic removal of water, was added 3-aminoquinoline (1.0 mmol) and boric acid (0.1 mmol) at room temperature and refluxed for 8 h. Upon completion (as monitored by TLC), the amide products were precipitated out from the reaction mixture by adding 40 mL n-hexane. The carboxamides were obtained via suction filtration, washed with n-hexane and dried over fused silica gel or concentrated using rotary evaporator and dried over vacuum in the case of oily products.

2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)acetamide (11a).
Yield (0.4489 g, 99.43%), brownish oil, FTIR (KBr, cm⁻¹): 3390 (NH), 3059 (C-H aromatic), 2967, 2874 (C-H aliphatic), 1701, 1687 (2C = O), 1606, 1584, 1454, 1424 (C = C), 1532 (N-O), 1356, 1327 (2S = O), 1169, 1146 (SO₂N), 1129, 1091, 1063, 1027, 1013, 1000 (C-N, C-O). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.44 (s, 1H, NH), 7.91 (d, J = 7.76 Hz, 3H, ArH), 7.74 (d, J = 8.24 Hz, 1H, ArH), 7.64 (d, J = 7.80 Hz, 1H, ArH), 7.55 (t, J = 6.40 Hz, 3H, ArH), 7.43 (m, 3H, ArH), 7.27 (m, 3H, ArH), 7.12 (m, 1H, ArH), 3.54 (s, 2H, CH₂), 2.28 (m, 3H, CH₃). ¹³C NMR (DMSO-d₆, 500MHz) δ: 170.8, 167.9 (C = O), 143.8, 143.2, 142.9, 141.4, 138.3, 133.4, 131.3, 130.0, 129.8, 129.4, 128.9, 128.9, 128.7, 128.7.
127.5, 127.0, 125.8, 124.6, 112.3 (nineteen aromatic carbons), 44.3, 21.4 (two aliphatic carbons). HRMS-ESI (m/z): 460.1265 (M+H), calculated, 460.1263.

2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-3-phenyl-N-(quinolin-3-yl)propanamide (11b). Yield (0.5401 g, 98.34%), brownish oil, FTIR (KBr, cm⁻¹): 3452 (NH), 3021 (C-H aromatic), 1682, 1659 (C = O), 1630 (C = N), 1601, 1497 (C = C), 1385, 1301 (2S = O), 1156, 1143 (SO₂N), 1092 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.40 (s, 1H, ArH), 8.13 (d, J = 9.16 Hz, 1H, ArH), 7.91 (d, J = 7.32 Hz, 1H, ArH), 7.72 (d, J = 8.24 Hz, 1H, ArH), 7.55 (t, J = 6.88 Hz, 1H, ArH), 7.44 (m, 3H, ArH), 7.30 (m, 3H, ArH), 7.16 (m, 5H, ArH), 7.08 (m, 4H, ArH), 6.55 (s, 1H, NH), 3.81 (m, 1H, CH-C = O), 2.88 (dd, J = 5.52, 5.96 Hz, 1H, CH₃ of CH₂), 2.65 (dd, J = 9.16, 9.20 Hz, 1H, CH₃ of CH₂), 2.26 (m, 3H, CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.8, 167.9 (C = O), 143.9, 142.9, 142.8, 142.1, 138.7, 137.9, 137.3, 133.4, 129.9, 129.8, 129.7, 129.4, 128.9, 128.7, 128.7, 126.9, 126.8, 126.1, 125.8, 124.4, 112.0 (twenty one aromatic carbons), 57.9, 38.4, 21.5 (three aliphatic carbons). HRMS-ESI (m/z): 548.1169 (M-H), calculated, 548.1165.

3-(1H-indol-2-yl)-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)propanamide (11c). Yield (0.5792 g, 98.47%), appearance, brown powder, mp, 88.10–88.80 °C, FTIR (KBr, cm⁻¹): 3413, 3373 (2NH), 3058 (C-H aromatic), 2922 (C-H aliphatic), 1702, 1698 (C = O), 1622 (C = N), 1597, 1494, 1457 (C = C), 1353, 1319 (2S = O), 1185, 1157 (SO₂N), 1091, 1011 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 10.74 (s, 1H, NH of indole), 8.40 (s, 1H, ArH), 7.01 (m, 2H, ArH), 6.87 (t, J = 7.32 Hz, 1H, ArH), 3.83 (m, 1H, CH-C = O), 3.01 (dd, J = 6.44, 6.40 Hz, 1H, CH₃ of CH₂), 2.79 (dd, J = 7.80, 7.76 Hz, 1H, CH₃ of CH₂), 2.26 (m, 3H, CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 173.2, 163.9 (C = O), 143.9, 142.9, 142.7, 141.5, 138.5, 136.6, 129.9, 129.8, 129.6, 129.4, 128.7, 127.4, 126.9, 126.8, 126.1, 125.8, 124.5, 124.4, 121.3, 118.8, 118.3, 111.9, 111.8, 109.4 (twenty five aromatic carbons), 57.1, 28.8, 21.5 (three aliphatic carbons). HRMS-ESI (m/z): 588.1834 (M⁺), calculated, 588.1831.

4-Methyl-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)pentanamide (11d). Yield (0.5010 g, 97.24%), brownish oil, FTIR (KBr, cm⁻¹): 3359 (NH), 3063 (C-H aromatic), 2957, 2871 (C-H aliphatic), 1700, 1692 (C = O), 1626 (C = N), 1602, 1584, 1495, 1452 (C = C), 1353, 1317 (2S = O), 1292, 1160 (SO₂N), 1094, 1072, 1026 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.45 (s, 1H, ArH), 8.02 (d, J = 8.72 Hz, 1H, ArH), 7.92 (t, J = 6.88 Hz, 1H, ArH), 7.75 (d, J = 8.28 Hz, 1H, ArH), 7.62 (d, J = 8.24 Hz, 1H, ArH), 7.57 (d, J = 8.42 Hz, 1H, ArH), 7.45 (t, J = 7.80 Hz, 1H, ArH), 7.31 (m, 2H, ArH), 7.19 (m, 3H, ArH), 7.11 (m, 5H, ArH), 6.53 (s, 1H, NH), 3.61 (t, J = 5.96 Hz, 1H, CH-C = O), 1.35 (m, 1H, CH), 1.20 (m, 2H, CH₂), 0.79 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 173.8, 167.9 (C = O), 143.5, 143.0, 142.9, 141.0, 138.9, 137.9, 133.4, 130.0, 129.9, 129.8, 129.4, 129.2, 129.1, 128.9, 128.7, 128.4, 127.1, 126.1, 125.8, 124.6, 112.5 (twenty one aromatic carbons), 54.5, 34.7, 23.1, 21.6, 14.5 (five aliphatic carbons). HRMS-ESI (m/z): 514.0101 (M-H), calculated, 514.0109.

3-Methyl-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)pentanamide (11e). Yield (0.4998 g, 97.01%), brownish oil, FTIR (KBr, cm⁻¹): 3363 (NH), 3063 (C-H aromatic), 2962, 2931, 2876 (C-H aliphatic), 1704, 1675 (C = O), 1627 (C = N), 1585, 1493, 1451 (C = C), 1317, 1304 (2S = O), 1258, 1159 (SO₂N), 1094, 1071, 1025 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.41 (s, 1H, ArH), 7.91 (m, 3H, ArH), 7.72 (d, J = 8.24 Hz, 1H, ArH), 7.58 (m, 3H, ArH), 7.45 (m, 2H, ArH), 7.30 (m, 3H, ArH), 7.12 (m, 2H, ArH), 3.48 (d, J = 5.96 Hz, 1H, CH-C = O), 2.31 (s, 3H, CH₃-Ar), 1.60 (m, 1H, CH), 1.32 (m, 1H, CH₂ of CH₂), 1.04 (m, 1H, CH₂ of CH₂), 0.70 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.7, 167.9 (C = O), 143.8, 142.9, 142.9, 141.3, 138.8, 133.4, 131.3, 130.0, 129.8, 129.4, 129.1, 128.9, 127.1,
126.9, 126.1, 124.5, 112.2 (seventeen aromatic carbons), 60.5, 37.4, 24.9, 21.5, 15.9, 11.4 (six aliphatic carbons). HRMS-ESI (m/z): 515.1889 (M⁺), calculated 515.1879.

3-Methyl-2-[N-(4-methylbenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)butanamide (11f). Yield (0.4979 g, 99.34%), brownish oil, FTIR (KBr, cm⁻¹): 3399 (NH), 1350 (2S = O), 1294, 1249, 1200, 1143, 1122, 1107 (thirteen aromatic carbons), 71.8, 66.9, 54.3, 33.5, 22.4 (aliphatic carbons). HRMS-ESI (m/z): 500.1604 (M-H), calculated 500.1606.

4-Hydroxy-1-(4-methylbenzenesulfonyl)-N-(quinolin-3-yl)pyrrolidine-2-carboxamide (11g). Yield (0.4111 g, 99.10%), brownish oil, FTIR (KBr, cm⁻¹): 3437 (OH), 3399 (NH), 2926 (C-H aliphatic), 1728 (C = O), 1631 (C = N), 1597, 1496, 1403 (C = C), 1332, 1305 (2S = O), 1198, 1156 (SO₂N), 1092, 1013 (C-N). ¹H NMR (DMSO-d₆, 400MHz): δ: 8.39 (s, 1H, ArH), 7.72 (d, J = 8.24 Hz, 1H, ArH), 7.64 (d, J = 8.24 Hz, 2H, ArH), 7.55 (d, J = 8.24 Hz, 1H, ArH), 7.28 (m, 2H, ArH), 4.17 (s, 1H, OH), 4.01 (t, J = 4.24 Hz, 1H, CH-C = O), 3.41 (m, 1H, CH-OH), 3.04 (d, J = 5.24 Hz, 2H, CH₂N), 2.35 (s, 3H, CH₃). HRMS-ESI (m/z): 411.1323 (M-H), calculated, 411.328.

1-(4-Methylbenzenesulfonyl)-N-(quinolin-3-yl)pyrrolidine-2-carboxamide (11h). Yield (0.3949 g, 99.95%), brownish oil, FTIR (KBr, cm⁻¹): 3435 (NH), 2979 (C-H aliphatic), 1700 (C = O), 1626 (C = N), 1602, 1597, 1498, 1440 (C = C), 1338, 1304 (2S = O), 1197, 1158 (SO₂N), 1063, 1013 (C-N). ¹H NMR (DMSO-d₆, 400MHz): δ: 8.44 (s, 1H, ArH), 7.73 (d, J = 8.24 Hz, 1H, ArH), 7.66 (d, J = 8.24 Hz, 2H, ArH), 7.55 (d, J = 7.76 Hz, 1H, ArH), 7.31 (m, 3H, ArH), 7.14 (m, 2H, ArH), 4.04 (t, J = 4.96 Hz, 1H, CH-C = O), 3.29 (m, 1H, CH₂ of CH₂N), 3.07 (m, 1H, CH₃ of CH₂N), 2.33 (s, 3H, CH₃), 1.76 (m, 3H), 1.47 (m, 1H, CH). ¹³C NMR (DMSO-d₆, 400MHz): δ: 173.7 (C = O), 143.9, 143.7, 134.9, 130.1, 129.4, 129.0, 128.7, 127.9, 126.9, 126.1, 125.9, 124.4, 111.9 (thirteen aromatic carbons), 68.9, 60.2, 56.8, 21.5 (four aliphatic carbons). HRMS-ESI (m/z): 395.1307 (M⁺), calculated, 395.1304.

2-[N-(benzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)acetamide (11i). Yield (0.4001 g, 89.89%), brownish oil, FTIR (KBr, cm⁻¹): 3391 (NH), 3071 (C-H aliphatic), 2835 (C-H aliphatic), 1688 (C = O), 1688 (C = O), 1623 (C = N), 1603, 1453, 1424 (C = C), 1350, 1325 (2S = O), 1187, 1129 (SO₂N), 1072, 1026 (C-N). ¹H NMR (DMSO-d₆, 500MHz): δ: 8.44 (s, 1H, ArH), 7.93 (d, J = 8.05 Hz, 3H, ArH), 7.74 (d, J = 8.10 Hz, 1H, ArH), 7.56 (t, J = 8.10 Hz, 2H, ArH), 7.46 (t, J = 8.05 Hz, 3H, ArH), 7.30 (m, 2H, ArH), 7.20 (t, J = 8.05 Hz, 2H, ArH), 7.11 (m, 2H, ArH), 2.25 (s, 3H, CH₃). ¹³C NMR (DMSO-d₆, 500MHz): δ: 167.9, 163.8 (C = O), 143.9, 142.9, 141.5, 137.9, 133.4, 131.3, 130.0, 129.8, 129.5, 129.4, 129.3, 129.1, 129.0, 128.7, 127.7, 126.9, 126.1, 125.8, 124.6, 112.4 (thirteen aromatic carbons), 60.9, 48.9, 30.9, 24.8, 21.5 (five aliphatic carbons). HRMS-ESI (m/z): 445.1112 (M⁺), calculated, 445.1096.

2-[N-(benzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)propanamide (11j). Yield (0.5300 g, 98.95%), appearance, white powder, 112.70–112.90 °C, FTIR (KBr, cm⁻¹): 3389 (NH), 3066 (C-H aliphatic), 1692, 1673 (C = O), 1623 (C = N), 1601, 1467 (C = C), 1343, 1321 (2S = O), 1178, 1154 (SO₂N), 1092, 1053 (C-N). ¹H NMR (DMSO-d₆, 400MHz): δ: 8.47 (d, J = 2.72 Hz, 1H, ArH), 8.27 (d, J = 8.72 Hz, 1H, ArH), 7.79 (d, J = 8.24 Hz, 2H, ArH), 7.61 (m, 1H, ArH), 7.55 (m, 2H, ArH), 7.48 (m, 2H, ArH), 7.38 (t, J = 8.24 Hz, 3H,
2-[N-(benzenesulfonyl)-1-phenylformamido]-3-(1H-indol-2-yl)-N-(quinolin-3-yl)propanamide (11k)
Yield (0.5701 g, 99.22%), appearance, white powder, mp, 73.50–73.80°C, FTIR (KBr, cm⁻¹): 3412, 3369 (2NH), 3002 (C-H aromatic), 2984 (C-H aliphatic), 1701, 1689 (C = O), 1622 (C = N), 1601, 1587, 1453 (C = C), 1342, 1309 (2S = O), 1185, 1134 (SO₂N), 1089, 1045 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 10.76 (s, 1H, NH), 8.39 (d, J = 2.72 Hz, 1H, ArH), 8.18 (s, 1H, ArH), 7.71 (d, J = 8.24 Hz, 1H, ArH), 7.55 (m, 3H, ArH), 7.47 (m, 2H, ArH), 7.31 (m, 6H, ArH), 7.09 (d, J = 2.76 Hz, 1H, ArH), 7.01 (m, 2H, ArH), 6.90 (t, J = 7.34 Hz, 1H, ArH), 3.86 (m, 1H, CH-C = O), 3.02 (dd, J = 6.88, 6.44 Hz, 1H, CH₃ of CH₂), 2.81 (dd, J = 7.80, 7.80 Hz, 1H, CH₃ of CH₂). ¹³C NMR (DMSO-d₆, 400MHz) δ: 173.1, 167.1 (C = O), 151.2, 143.9, 142.9, 141.4, 141.6, 133.9, 133.3, 132.6, 130.0, 129.9, 129.8, 129.4, 129.2, 129.0, 128.7, 127.5, 126.9, 126.7, 126.1, 124.4, 118.9, 118.4, 111.9, 109.4 (twenty five aromatic carbons), 57.2, 28.8 (two aliphatic carbons). HRMS-ESI (m/z): 537.2795 (M-H), calculated, 537.2796.

2-[N-(benzenesulfonyl)-1-phenylformamido]-4-methyl-N-(quinolin-3-yl)pentanamide (11l)
Yield (0.4912 g, 98.00%), appearance, white powder, 132.40–132.80°C, FTIR (KBr, cm⁻¹): 3362 (NH), 3062 (C-H aromatic), 2958 (C-H aliphatic), 1704, 1687 (C = O), 1628 (NO₂), 1603, 1450 (C = C), 1353, 1315 (2S = O), 1260, 1163 (SO₂N), 1094, 1071, 1025 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.40 (s, 1H, ArH), 8.11 (d, J = 8.72 Hz, 2H, ArH), 7.91 (d, J = 6.84 Hz, 2H, ArH), 7.71 (d, J = 1.84 Hz, 3H, ArH), 7.51 (m, 5H, ArH), 7.31 (m, 3H, ArH), 3.59 (m, 1H, CH-C = O), 1.50 (m, 1H, CH), 1.32 (m, 2H, CH₂), 0.71 (m, 6H, CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 173.8, 162.7 (C = O), 143.9, 142.9, 141.6, 141.4, 138.7, 134.3, 133.4, 132.8, 129.8, 129.5, 129.1, 128.9, 126.9, 126.1, 124.4, 112.0, 100.0 (seventeen aromatic carbons), 54.5, 41.4, 24.4, 23.1 (four aliphatic carbons). HRMS-ESI (m/z): 500.1563 (M-H), calculated, 500.1568.

2-[N-(benzenesulfonyl)-1-phenylformamido]-3-methyl-N-(quinolin-3-yl)pentanamide (11m)
Yield (0.4514 g, 90.06%), appearance, brown powder, 145.10–145.30°C, FTIR (KBr, cm⁻¹): 3361 (NH), 3062 (C-H aromatic), 2933, 2877 (C-H aliphatic), 1704, 1687 (C = O), 1627 (C = N), 1603, 1584, 1500 (1449 = C), 1353, 1315 (2S = O), 1259, 1162 (SO₂N), 1093, 1071, 1025 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.42 (d, J = 2.76 Hz, 1H, ArH), 7.91 (m, 2H, ArH), 7.74 (m, 2H, ArH), 7.51 (m, 5H, ArH), 7.29 (m, 3H, ArH), 7.19 (t, J = 7.32 Hz, 1H, ArH), 7.09 (m, 2H, ArH), 3.52 (d, J = 2.76 Hz, 1H, CH-C = O), 1.61 (m, 1H, CH), 1.30 (m, 1H, CH₃ of CH₂), 1.04 (m, 1H, CH₃ of CH₂), 0.71 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.7, 167.9 (C = O), 143.8, 142.9, 141.7, 141.4, 133.4, 132.8, 131.3, 130.0, 129.8, 129.4, 129.1, 128.9, 128.7, 127.0, 126.9, 126.1, 125.8, 124.5, 112.1 (nineteen aromatic carbons), 60.6, 37.4, 24.9, 15.9, 11.4 (five aliphatic carbons). HRMS-ESI (m/z): 501.1742 (M⁺), calculated, 501.1742.

2-[N-(benzenesulfonyl)-1-phenylformamido]-3-methyl-N-(quinolin-3-yl)butanamide (11n)
Yield (0.4511 g, 92.59%), brownish oil, FTIR (KBr, cm⁻¹): 3361 (NH), 3063 (C-H aromatic), 2966 (C-H aliphatic), 1703, 1664 (C = O), 1627 (C = N), 1603, 1584, 1498, 1450 (C = C), 1353, 1316 (2S = O), 1273, 1164 (SO₂N), 1094, 1071, 1025, 1000 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.46 (s, 1H, ArH), 8.01 (m, 3H, ArH), 7.76 (t, J = 8.05 Hz, 2H, ArH), 7.50 (m, 5H, ArH), 7.30 (m, 3H, ArH), 7.19 (t, J = 8.05 Hz, 1H, ArH), 7.10 (m, 2H, ArH), 3.51 (d, J = 6.44 Hz, 1H, CH-C = O), 1.92 (m, 1H, CH), 0.76 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.8, 167.9 (C = O), 143.9, 142.9, 141.7, 141.5, 137.9, 133.4, 131.3,
129.8, 129.4, 129.1, 128.9, 128.7, 127.0, 126.9, 126.1, 125.8, 124.5 (eighteen aromatic carbons), 61.8, 30.9, 19.5, 18.3 (four aliphatic carbons). HRMS-ESI (m/z): 486.1435 (M-H), calculated, 486.1437.

1-(Benzenesulfonyl)-4-hydroxy-N-(quinolin-3-yl)pyrrolidine-2-carboxamide (11o). Yield (0.3970 g, 99.89%), brownish oil, FTIR (KBr, cm⁻¹): 3416 (OH), 3365 (NH), 3065 (C-H aromatic), 2974, 2879 (C-H aliphatic), 1701 (C = O), 1618 (C = N), 1601, 1447 (C = C), 1384, 1332 (2S = O), 1172, 1157 (SO₂N), 1092, 1045 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.42 (s, 1H, ArH), 7.75 (m, 3H, ArH), 7.60 (m, 4H, ArH), 7.25 (m, 2H, ArH), 7.11 (s, 1H, ArH), 6.69 (s, 1H, NH), 4.18 (s, 1H, OH), 4.05 (t, J = 7.80 Hz, 1H, CH-C = O), 3.43 (m, 1H, CH-OH), 3.10 (d, J = 5.24 Hz, 2H, CH₃N), 1.92 (m, 2H, CH₂). ¹³C NMR (DMSO-d₆, 400MHz) δ: 173.8 (C = O), 143.9, 141.5, 137.8, 133.5, 129.6, 129.4, 128.9, 128.7, 127.9, 126.9, 126.1, 125.8, 124.5, 112.1 (thirteen aromatic carbons), 68.9, 60.2, 56.9, 23.0 (four aliphatic carbons). HRMS-ESI (m/z): 398.1172 (M+H), calculated, 398.1176.

1-(Benzenesulfonyl)-N-(quinolin-3-yl)pyrrolidine-2-carboxamide (11p). Yield (0.3813 g, 99.98%), brownish oil, FTIR (KBr, cm⁻¹): 3417 (NH), 3063 (C-H aromatic), 2978, 2877 (C-H aliphatic), 1725 (C = O), 1619 (C = N), 1499, 1446 (C = C), 1384, 1339 (2S = O), 1198, 1160 (SO₂N), 1094, 1072, 1016 (C-N). ¹H NMR (DMSO-d₆, 500MHz) δ: 8.41 (s, 1H, ArH), 7.79 (t, J = 6.85 Hz, 2H, ArH), 7.73 (d, J = 8.00 Hz, 1H, ArH), 7.66 (t, J = 7.45 Hz, 1H, ArH), 7.58 (m, 3H, ArH), 7.30 (m, 1H, ArH), 7.21 (t, J = 7.45 Hz, 1H, ArH), 7.11 (m, 1H, ArH), 6.50 (s, 1H, NH), 4.07 (m, 1H, CH-N = C = O), 3.33 (m, 1H, CH₂ of CH₂N), 3.12 (m, 1H, CH₂ of CH₃N), 1.81 (m, 3H), 1.52 (m, 1H, CH). ¹³C NMR (DMSO-d₆, 500MHz) δ: 173.7 (C = O), 143.8, 142.9, 141.3, 138.0, 133.6, 129.9, 129.4, 128.9, 128.7, 127.6, 127.0, 126.1, 125.9, 124.5, 112.2 (fifteen aromatic carbons), 60.9, 48.9, 30.9, 24.8 (four aliphatic carbons). HRMS-ESI (m/z): 399.2098 (M+NH₄), calculated, 399.2096.

2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)acetamide (11q). Yield (0.4889 g, 99.76%), appearance, white powder, mp, 102.80–102.90°C, FTIR (KBr, cm⁻¹): 3377 (NH), 3091 (C-N aromatic), 1745, 1672 (C = O), 1619 (C = N), 1601, 1437 (C = C), 1527 (NO₂), 1350, 1306 (2S = O), 1256, 1161 (SO₂N), 1092 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.70 (d, J = 9.16 Hz, 1H, ArH), 8.64 (m, 2H, ArH), 8.13 (m, 2H, ArH), 7.91 (m, 2H, ArH), 7.23 (m, 2H, ArH), 7.59 (m, 1H, ArH), 7.45 (m, 1H, ArH), 7.35 (m, 1H, ArH), 7.22 (m, 2H, ArH), 7.07 (m, 2H, ArH), 3.13 (s, 2H, CH₂). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.7, 167.9 (C = O), 147.1, 143.1, 142.7, 134.9, 130.1, 129.8, 129.7, 129.4, 129.1, 128.9, 128.7, 128.6, 128.2, 127.8, 127.4, 126.2, 125.2, 124.7 (seventeen aromatic carbons), 58.2 (aliphatic carbons). HRMS-ESI (m/z): 490.1714 (M’), calculated, 490.1708.

2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]-3-phenyl-N-(quinolin-3-yl)propamamide (11r). Yield (0.5529 g, 95.48%), brownish oil, FTIR (KBr, cm⁻¹): 3359 (NH), 3063 (C-H aromatic), 1705, 1697 (C = O), 1602 (C = N), 1584, 1499, 1451 (C = C), 1350, 1315 (2S = O), 1165, 1118 (SO₂N), 1088, 1071, 1025 (C-N). ¹H NMR (DMSO-d₆, 400MHz) δ: 8.44 (m, 1H, ArH), 8.33 (m, 1H, ArH), 8.15 (d, J = 9.16 Hz, 1H, ArH), 8.02 (d, J = 9.16 Hz, 1H, ArH), 7.91 (m, 3H, ArH), 7.72 (t, J = 7.32 Hz, 2H, ArH), 7.56 (m, 2H, ArH), 7.45 (m, 3H, ArH), 7.30 (m, 3H, ArH), 7.12 (d, J = 6.58 Hz, 2H, ArH), 7.07 (m, 1H, ArH), 3.95 (m, 1H, CH-C = O), 2.96 (dd, J = 5.04, 5.04 Hz, 1H, CH₂ of CH₃N), 2.68 (dd, J = 10.08, 10.08 Hz, 1H, CH₂ of CH₃N). ¹³C NMR (DMSO-d₆, 400MHz) δ: 172.7, 167.9 (C = O), 143.8, 142.9, 141.3, 137.2, 133.4, 131.3, 130.0, 129.8, 129.7, 129.4, 129.1, 128.9, 128.7, 128.6, 128.2, 126.9, 126.9, 126.1, 124.9, 124.7, 124.5, 112.2 (twenty one aromatic carbons), 58.2, 38.1 (two aliphatic carbons). HRMS-ESI (m/z): 597.1860 (M+NH₄), calculated, 597.1864.

3-(1H-indol-2-yl)-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl) propanamide (11s). Yield (0.6089 g, 98.34%), appearance, white powder, mp, 147.70–147.90°C, FTIR (KBr, cm⁻¹): 3416, 3387 (NH), 3076 (C-H aromatic), 1710, 1684 (C = O), 1627
Synthesis of new anti-trypanosomal agents

4-Methyl-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)pentanamide (11t). Yield (0.5401 g, 98.88%), brownish oil, FTIR (KBr, cm⁻¹): 3388 (NH), 3065 (C-H aromatic), 2955 (C-H aliphatic), 1701, 1688 (C = O), 1631 (C = N), 1604, 1452 (C = C), 1524 (NO₂), 1353, 1315 (2S = O), 1172, 1123 (SO₂N), 1018 (C-N). ¹H NMR (DMSO-d₆, 500MHz): δ: 8.54 (d, J = 8.60 Hz, 1H, ArH), 8.43 (s, 1H, NH), 8.35 (d, J = 9.15 Hz, 2H, ArH), 8.01 (d, J = 6.90 Hz, 2H, ArH), 7.73 (d, J = 8.05 Hz, 2H, ArH), 7.57 (m, 3H, ArH), 7.46 (t, J = 7.45 Hz, 3H, ArH), 7.30 (m, 3H, ArH), 7.20 (t, J = 7.45 Hz, 1H, ArH), 7.11 (m, 3H, ArH), 3.73 (t, J = 5.70 Hz, 1H, CH-C = O), 1.57 (m, 1H, CH), 1.40 (m, 2H, CH₂), 0.76 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 500MHz): δ: 173.4, 164.7 (C = O), 147.3, 143.9, 142.9, 141.4, 137.9, 133.4, 131.3, 130.0, 129.8, 129.4, 129.1, 128.9, 128.7, 128.7, 128.6, 126.1, 125.8, 124.8, 124.4, 121.2 (twenty aromatic carbons), 54.7, 24.5, 23.1, 21.6, 21.4 (five aliphatic carbons). HRMS-ESI (m/z): 547.0836 (M+H⁺), calculated, 547.0839.

3-Methyl-2-[N-(4-nitrobenzenesulfonyl)-1-phenylformamido]-N-(quinolin-3-yl)pentanamide (11u). Yield (0.5392 g, 98.72%), brownish oil, FTIR (KBr, cm⁻¹): 3345 (NH), 3066 (C-H aromatic), 2959, 2876 (C-H aliphatic), 1695, 1689 (C = O), 1603 (C = N), 1584, 1451 (C = C), 1530 (NO₂), 1350, 1314 (2S = O), 1172, 1137 (SO₂N), 1092, 1070, 1025 (C-N). ¹H NMR (DMSO-d₆, 400MHz): δ: 8.33 (m, 2H, ArH), 8.01 (m, 1H, ArH), 7.91 (m, 2H, ArH), 7.73 (d, J = 8.24 Hz, 1H, ArH), 7.57 (m, 2H, ArH), 7.45 (m, 3H, ArH), 7.31 (m, 2H, ArH), 7.19 (m, 1H, ArH), 7.09 (m, 2H, ArH), 3.62 (d, J = 3.20 Hz, 1H, CH-C = O), 1.70 (m, 1H, CH), 1.32 (m, 1H, CH₂ of CH₃), 1.06 (m, 1H, CH₃ of CH₂), 0.76 (m, 6H, 2CH₃). ¹³C NMR (DMSO-d₆, 400MHz): δ: 172.4, 167.9 (C = O), 149.9, 147.2, 143.6, 141.1, 137.9, 133.4, 131.3, 130.0, 129.8, 129.4, 129.1, 128.7, 128.7, 128.6, 126.1, 125.8, 124.8, 124.4, 112.1 (twenty aromatic carbons), 54.7, 24.5, 23.1, 21.6, 21.4 (five aliphatic carbons). HRMS-ESI (m/z): 546.1582 (M⁺), calculated, 546.1573.

4-Hydroxy-1-(4-nitrobenzenesulfonyl)-N-(quinolin-3-yl)pyrrolidine-2-carboxamide (11w). Yield (0.4421 g, 100%), appearance, white powder, mp, 80.20–80.90°C, FTIR (KBr, cm⁻¹): 3428 (OH), 3332 (NH), 3054 (C-H aromatic), 2945, 2876 (C-H aliphatic), 1687 (C = O), 1641 (C = N), 1609, 1572, 1471, 1435 (C = C), 1534 (NO₂), 1347, 1290 (2S = O), 1190, 1129
(SO₂N), 1019 (C-N). $^1$H NMR (DMSO-$d_6$, 400MHz) δ: 8.36 (d, J = 8.68 Hz, 2H, ArH), 8.02 (d, J = 8.72 Hz, 2H, ArH), 7.72 (d, J = 8.24 Hz, 1H, ArH), 7.56 (d, J = 7.80 Hz, 1H, ArH), 7.31 (m, 2H, ArH), 7.11 (m, 1H, ArH), 7.03 (s, 1H, CH₂), 6.48 (s, 1H, OH), 4.17 (s, 1H, OH), 4.10 (t, J = 3.96 Hz, 1H, CH-C = O), 3.44 (m, 1H, CH₂), 2.01 (m, 1H, CHa of CH₂), 1.90 (m, 1H, CHb of CH₂).

$^{13}$C NMR (DMSO-$d_6$, 400MHz) δ: 173.5 (C = O), 150.3, 143.9, 143.6, 142.9, 129.9, 129.5, 129.0, 126.9, 126.1, 124.8, 124.5, 118.7, 112.0 (thirteen aromatic carbons), 69.0, 60.5, 57.1, 29.1 (four aliphatic carbons). HRMS-ESI (m/z): 441.0871 (M-H), calculated, 441.0872.

1-(4-Nitrobenzene sulfonyl)-N-(quinolin-3-yl)pyrrolidine-2-carboxamide (11x).

Yield (0.4201 g, 98.59%), appearance, white powder, mp, 89.20–90.10˚C, FTIR (KBr, cm$^{-1}$): 3367 (NH), 3104 (C-H aromatic), 2981 (C-H aliphatic), 1691 (C = O), 1623 (C = N), 1607, 1499, 1473 (C = C), 1529 (NO₂), 1350, 1304 (2S = O), 1199, 1163 (SO₂N), 1106, 1011 (C-N). $^1$H NMR (DMSO-$d_6$, 500MHz) δ: 8.39 (t, J = 8.60 Hz, 2H, ArH), 8.06 (d, J = 9.15 Hz, 2H, ArH), 7.55 (d, J = 8.60 Hz, 1H, ArH), 7.31 (m, 2H, ArH), 7.21 (t, J = 7.45 Hz, 1H, ArH), 7.11 (m, 1H, ArH), 4.18 (dd, J = 4.00, 4.00 Hz, 1H, CH-C = O), 3.37 (m, 1H, CH of CH₂), 3.21 (m, 1H, CH of CH₂), 1.96 (m, 1H, CH of CH₂), 1.81 (m, 2H, CH₂), 1.63 (m, 1H, CH of CH₂). $^{13}$C NMR (DMSO-$d_6$, 400MHz) δ: 173.4 (C = O), 150.4, 143.9, 142.9, 141.6, 130.0, 129.2, 129.1, 128.7, 126.9, 126.0, 125.1, 124.4, 111.9 (thirteen aromatic carbons), 61.1, 48.9, 30.9, 24.7 (four aliphatic carbons). HRMS-ESI (m/z): 427.1075 (M+H), calculated, 427.1077.

Pharmacokinetic prediction

The drug-likeness was predicted using online quantitative estimation of drug-likeness tools. The prediction was based on the calculated logP, topological polar surface area (TPSA), hydrogen bond donors (HBD), hydrogen bond acceptor (HBA), number of acid (NA), molecular weight (MW), number of rotatable bonds (NRB) and percentage absorption (ABS). The prediction tool was accessed from crdd.osdd.net/oscadd/qed/submit_virtual.php, molinspiration and druglito.

In vitro antitrypanosomal activities

In vitro antitrypanosomal activities against $T. b. gambiae$ strain was described by Otoguro et al [25]. In brief, $T. b. gambiae$ strain was cultured in IMDM with various supplements and 10% heat-inactivated FBS at 37˚C, under 5.0% CO₂/95% air according to the method of Baltz et al [26]. Ninety five mL of the trypanosomes suspension (2.0–2.510⁴ trypanosomes/mL for strain GUTat 3.1) was seeded in a 96-well microplate, and 5.0 mL of a test compound solution (dissolved in 5.0% dimethylsulfoxide) was added followed by incubation for 72 h (long incubation-low inoculation test: LILIT). Ten mL of the fluorescent dye Alamar Blue was added to each well. After incubation for 3–6 h, the resulting solution was read at 528/20 nm excitation wavelength and 590/35 nm emission wavelength by a FLx800 fluorescent plate reader (Bio-Tek Instrument, Inc. Vermont, USA). Data were transferred into a spreadsheet program (Excel). The IC₅₀ values were determined using fluorescent plate reader software (KC-4, Bio-Tek). Successive subcultures were done in 24-well tissue culture plates under the same conditions.

Determination of LD₅₀ for the active anti-inflammatory compounds

Male mice were divided into various groups and test compounds were administered in various doses intraperitoneally. Following treatments, the animals were observed for up to 4 h continuously and were then kept under observation for 72 h. All behavioral changes and deaths during the observation periods were recorded. The percentage of death at each dose level was then calculated, converted to probits and the LD₅₀ (μM/kg) values were calculated [27]. To observe
the health status of the mice, they were monitored 4 times a day. Humane endpoints were used when the animal shows sign of weight loss, weakness accompanied by inability to get food, complete anorexia and convulsion for 24 h. For the purpose of ameliorating the suffering of the dying mice, CO$_2$ euthanasia was applied. All the dead mice were disposed in bio-safety containers in accordance with local standard protocols. The mortality rate in each group was calculated according to the formula:

\[
\text{Mortality rate(\%)} = \left( \frac{\text{the number of dead mice}}{\text{the number of mice in the group}} \right) \times 100
\]

**Results and discussion**

To assess the effect of electron density, we decided to study several benzenesulphonamides bearing electron-rich and deficient substituents (Figs 2 and 3). In the first step, the substituted benzenesulphonamides (7a-x) were synthesized by the reaction of substituted benzenesulphonyl chlorides (5a-c) with amino acids (6a-h) in the presence of sodium carbonate as base (Fig 2). The N-benzoylated derivatives (9a-f, 9i-n and 9q-v) were obtained by the reaction of the appropriate benzenesulphonamides (7a-x) with benzoyl chloride (8) in the presence of sodium hydroxide (Fig 2). Boric acid catalysed amidation of the carboxylic acid end of the N-benzoylated derivatives (9a-f, 9i-n and 9q-v) and 3-aminoquinoline (10) afforded the corresponding carboxamide derivatives (11a-f, 11i-n and 11q-v) (Fig 2). In addition to the N-benzoylated derivatives, the proline and 4-hydroxyproline derivatives of substituted benzenesulphonamides (7g, h, o, p, w and x) were also reacted with 3-aminoquinoline in the same manner to afford the carboxamide sulphonamide derivatives 11g, h, o, p, w and x. The carboxamides were crystallized in their analytical grade using n-hexane. The synthesized compounds were characterized by various spectroscopic techniques like FTIR, $^1$H NMR, $^{13}$C NMR and high resolution mass spectroscopy (HRMS). The presence of a sharp bands between 3448–3415 cm$^{-1}$, 3385–3248 cm$^{-1}$ and 1753–1699 cm$^{-1}$ assigned to OH of carboxylic acid, NH and C = O respectively were indicative of successful formation of compounds 7a-x. The disappearance of the N-H band at 3385–3248 cm$^{-1}$ in the N-benzoylated derivatives coupled with the appearance of an additional band at 1685–1689 cm$^{-1}$ is diagnostic of the successful N-benzoylation of the substituted benzenesulphonamides. In the $^1$H NMR spectra of the N-benzoylated derivatives, the disappearance of the NH peak and the appearance of additional aromatic peaks having five protons were indicative of successful coupling. In the $^{13}$C NMR, the appearance of four additional aromatic carbons and a peak at 167 ppm were diagnostic of successful N-benzoylation.

The IR of all the new carboxamides showed a sharp band between 3452–3359 cm$^{-1}$ and 1632–1622 cm$^{-1}$ corresponding to the NH and C = N band respectively. In the $^1$H NMR, the singlet appearing between 8.46–8.40 ppm in the derivatives corresponds to the one aromatic proton of 3-aminoquinoline group; the peak at 6.54–6.50 ppm corresponds to the singlet peak of the NH group in the carboxamide derivatives. In the $^{13}$C NMR spectra, the appearance of additional nine aromatic peaks corresponds to the nine carbons of the 3-aminoquinoline. These spectral characterizations, in addition to the HRMS-ESI spectra which showed the molecular ion peaks of the compounds, were supportive of the successful formation of the final products. The aromatic and aliphatic protons and carbons appeared at the predicted range using BioDraw.

**In vitro antitrypanosomal activities and structure-activity relationship**

The results of the *in vitro* antitrypanosomal activities (Fig 4), revealed that compounds 11f, 11g, 11h, 11i, 11o, 11p, 11v, 11w and 11x had IC$_{50}$ values of 3, 2, 5, 1, 3, 4, 1, 2, 3 nM respectively which in exception of compounds 11h and 11p were 2-fold, 3-fold, 5-fold, 2-fold, 5-fold,
3-fold and 2-fold more active than melarsoprol (IC50 5 nM). These derivatives with good antitrypanosomal activity against *T. b. gambiae* could serve either as a replacement to melarsoprol and pentamidine where there is record of toxicity or as a new entrant to HAT chemotherapy. The L-valine, L-hydroxyproline and L-proline derivatives were the most active compounds in each of the series. The 4-nitrobenzenesulphonamide derivatives were found to be more active than the unsubstituted benzenesulphonamide and 4-methylbenzenesulphonamide derivatives. The p-nitrobenzenesulphonamides were the most active derivatives followed...
### Fig 3. Structures of the new derivatives

A structural representation of the new derivatives.

[1](https://doi.org/10.1371/journal.pone.0191234.g003)
### Table: In vitro antitrypanosomal activities

| Sample no. | IC<sub>50</sub> (nM) | LD<sub>50</sub> μM/kg |
|------------|----------------------|----------------------|
| 11a        | 136±0.03             |                      |
| 11b        | 114±0.05             |                      |
| 11c        | 106±0.03             |                      |
| 11d        | 121±0.05             |                      |
| 11e        | 121±0.04             |                      |
| 11f        | 3±0.01               | 15.61±0.13           |
| 11g        | 2±0.01               | 13.09±0.22           |
| 11h        | 6±0.07               | 18.02±0.18           |
| 11i        | 140±0.03             |                      |
| 11j        | 116±0.04             |                      |
| 11k        | 109±0.08             |                      |
| 11l        | 125±0.10             |                      |
| 11m        | 125±0.09             |                      |
| 11n        | 1±0.03               | 11.02±0.21           |
| 11o        | 3±0.04               | 10.23±0.18           |
| 11p        | 4±0.06               | 12.56±0.29           |
| 11q        | 128±0.09             |                      |
| 11r        | 108±0.09             |                      |
| 11s        | 101±0.07             |                      |
| 11t        | 114±0.09             |                      |
| 11u        | 114±0.03             |                      |
| 11v        | 1±0.04               | 9.21±0.20            |
| 11w        | 2±0.03               | 9.06±0.16            |
| 11x        | 3±0.06               | 9.93±0.18            |
| melarsoprol| 5±0.08               | 7.21±0.28            |

*Fig 4. In vitro antitrypanosomal activities. A table of value representing the in vitro antitrypanosomal activities.*

[https://doi.org/10.1371/journal.pone.0191234.g004](https://doi.org/10.1371/journal.pone.0191234.g004)
by the p-toluenesulphonamides and then the benzenesulphonamides. These findings underscore the importance of a substituent at the para position of the benzene ring in the antitrypanosomal activity. In general, the effect of the substituents on the benzene ring followed the trend NO₂ > CH₃ > H. The effect of the amino acid residue showed that the L-valine derivatives (11f, 11n and 11v) had better activity than the L-leucine (11d, 11l and 11t), L-isoleucine (11e, 11m and 11u) and glycine (11a, 11i and 11q) derivatives. This shows that the chain length of a substituent at the β-carbon contributes significantly to biological activity. The effect of the presence of a substituent at the β-carbon was shown by the biological activity of the L-leucine, L-isoleucine and L-valine derivatives which were better than the glycine derivatives that lacked substitution at the β-carbon. Among the aromatic amino acids, the L-tryptophan (11c, 11k and 11s) were more active than the L-phenylalanine (11b, 11j and 11r), this may not be unconnected with the presence of nitrogen on the ring. The L-4-hydroxyproline (11g, 11o and 11w) were more active than their corresponding L-prolines (11h, 11p and 11x) which highlights the importance of the hydroxyl group on biological activity of the molecules.

The LD₅₀ values showed that the most promising hits in exception of the p-nitrobenzenesulphonamide derivatives (11v-x) had better toxicity profile than melarsoprol and as such may likely not have the toxicity problems associated with melarsoprol and other antitrypanosomal agents currently in use. Compound 11h was the safest hit with LD₅₀ of 18.02 μM/kg. The p-toluenesulphonamide derivatives (11f-h) were the safest derivatives followed by the benzenesulphonamide derivatives (11n-p).

**In silico calculation of the pharmacokinetics properties (ADME-T) and drug-likeness**

Drug-likeness describes an integrated equilibrium between multiple molecular properties and structural features that define whether a particular compound is comparable to known drugs. Lipinski’s rule of 5 (ro5) is among the most common principle applied to evaluate drug-likeness properties of a compound [28]. Verber’s criteria have also been applied extensively to evaluate oral bioavailability of compounds [29]. These properties measure hydrophilicity, electronic distribution, hydrogen bonding capability, molecule size and flexibility that would affect molecules behaviours in a living system. The behavior predicted includes bioavailability, transport properties, affinity to proteins reactivity and toxicity [30].

A computational studies of all the carboxamides 11a-x using DrugLiTo and MedChem Designer 3.0 software was carried out to determine the Lipinski’s molecular properties, the blood-brain barrier likeness, and the number of rotatable bonds (NRB), together with the topological polar surface area (TPSA; a sum of polar atoms surfaces, a descriptor for drug absorption, penetrability and bioavailability) and the percentage of absorption (ABS %) calculated as (ABS % = 109 – 0.345 × TPSA) [31].

The results of the pharmacokinetics prediction (Fig 5) revealed that all the tested compounds in exception of compound 11c complied with ro5 where LogP values ranged between -0.154 and 4.650 (≤ 5), MW range 381–619 (≤ 500 but one violation is permissible for ro5), HBA range 4–6 (≤ 10), HBD range 1–2 (≤ 5), suggesting that these compounds would not be expected to cause oral bioavailability problems. Compound 11c needs derivatization to improve on its oral bioavailability profile. In exception of compounds 11r-11u (NRB = 11), all the compounds showed NRB values range 5–10 (≤ 10), indicating acceptable molecular flexibility with consequent expected good permeability and oral bioavailability. Additionally, all the compounds evaluated showed TPSA range 75.19–135.40 Å² (≤ 140 Å²), showing good permeability and transport of the compounds in the cellular plasma membrane. Furthermore, all the tested compounds exhibited a considerable %ABS range 62.29–83.06% which is a
designation of good bioavailability upon oral administration. Finally, since sleeping sickness occurs when single-cell trypanosome parasites spread from to brain over the blood-brain barrier, the BBB likeness of the compounds were evaluated. All the evaluated compounds showed NA values 0 (0), HBA range 4–6 (<10) and MW range 381–619 (<500), indicating that

![Fig 5. Pharmacokinetic properties in vitro antitrypanosomal activities. A table of value representing the in vitro antitrypanosomal activities.](https://doi.org/10.1371/journal.pone.0191234.g005)
compounds 11b-11e, 11j-11k and 11r-11v cannot cross the blood-brain barrier and as such would not succeed in the treatment of second stage of human African trypanosomiasis. It is important to note that the more active derivatives in the in vitro antitrypanosomal activities study (11f-h, 11n-p and 11v-x) had fascinating pharmacokinetics properties.

**Conclusion**

Despite the fact that over 100,000 death annually is attributed to trypanosome, there is currently no new drug for the treatment of trypanosome. Although efornithine was introduced in the 90’s, it was found to be ineffective against *T. b. rhodesiense*. The development of resistance species to existing antitrypanosomal agent is quite worrisome. We have presented an efficient, eco-friendly, highly yielding and versatile direct amidation procedure for unactivated carboxylic acids bearing benzenesulphonamides. Beside the synthetic procedure reported, the compounds were found to possess fascinating antitrypanosomal activities against *T. b. gambiense*. Some of these derivatives reported herein was found to be more active than melarsoprol. The novel compounds showed satisfactory predicted physico-chemical properties including oral bioavailability, permeability and transport properties.

**Supporting information**

S1 File. ¹H and ¹³C spectra of the new derivatives. (DOC)

**Acknowledgments**

Authors are thankful to Prof. Sandeep Verma of the Department of Chemistry, Indian Institute of Technology, Kanpur for providing the facilities for synthesis and spectral characterization. We are also thankful to the department of biological science and bioengineering IIT, Kanpur for helping in the in silico analysis. We are also thankful to the department of Veterinary Parasitology and Entomology, University of Nigeria, Nsukka for the in vitro antitrypanosomal activities study.

**Author Contributions**

Conceptualization: David Izuchukwu Ugwu, Uchechukwu Chris Okoro.

Data curation: David Izuchukwu Ugwu, Narendra Kumar Mishra.

Formal analysis: David Izuchukwu Ugwu, Narendra Kumar Mishra.

Funding acquisition: David Izuchukwu Ugwu.

Investigation: David Izuchukwu Ugwu.

Methodology: David Izuchukwu Ugwu, Uchechukwu Chris Okoro, Narendra Kumar Mishra.

Project administration: David Izuchukwu Ugwu, Uchechukwu Chris Okoro.

Resources: David Izuchukwu Ugwu.

Software: David Izuchukwu Ugwu, Narendra Kumar Mishra.

Supervision: David Izuchukwu Ugwu, Uchechukwu Chris Okoro.

Validation: David Izuchukwu Ugwu.

Visualization: David Izuchukwu Ugwu.
Writing – original draft: David Izuchukwu Ugwu.

Writing – review & editing: David Izuchukwu Ugwu, Uchechukwu Chris Okoro.

References

1. Barret MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al (2003) The trypanosomiasis. Lancet 362(9394): 1469–1480. https://doi.org/10.1016/S0140-6736(03)14694-6 PMID: 14602444

2. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiens. a randomized trial. Lancet 355: 1419. https://doi.org/10.1016/S0140-6736(00)02141-3 PMID: 10791526

3. Lescure FX (2010) Chagas disease: changes in knowledge and management (review). Lancet Infectious Disease 10(8): 556–570

4. Trypanosomiasis, human African (sleeping sickness) World Health Organisation. www.who.int/mediacentre/factsheets/fs259/en retrieved on 12th May, 2017.

5. Trypanosoma brucei gambiens and Trypanosoma brucei rhodesiens (African Trypanosomiasis) infectious disease and antimicrobial agents. www.antimicrobe.org retrieved on 17th November, 2016, accessed on 12th May, 2017.

6. Hollingham R (2005) Curing diseases modern medicine has left behind. New Scientists 2482:40–44.

7. Pentamidine Isethionate (2016) The American Society of Health-System Pharmacists. www.drugs.com/monograph/pentamidine-isethionate.html Accessed May 12, 2017.

8. Pentamidine side effects in details. www.drugs.com/sfx/pentamidine-side-effects.html accessed 12th May, 2017.

9. DailyMed-PENTAM 300 pentamidine isethionate infection, powder, lyophilized, for solution. www.dailymed.nlm.nih.gov accessed 12th May, 2017.

10. DrugBank ed (2016) Pentamidine. www.drugbank.ca/drugs/DB00738 accessed on 13th May, 2017.

11. Coura JR, de Castro SL (2002) A critical review of Chagas disease chemotherapy. Memorias do Instituto Oswaldo Cruz, 97(1): 3–24. PMID: 11992141

12. Jackson Y, Alirol E, Getaz L, Wolff H, Combesure C, Chappuis F (2010) Tolerance and safety of Nifurtimox in patients with chronic Chagas disease. Clinical Infectious Diseases. 51(10): e69–e75. https://doi.org/10.1086/656917 PMID: 20932171

13. Pepin J, Milord F, Mpiia B (1989). An open clinical trial of nifurtimox for arseno-resistant T. b. gambiens sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 83(4): 514–517. PMID: 2694491

14. Schaefer C, Peters PWJ, Miller RK (2014) Drugs during pregnancy and lactation: treatment options and risk assessment. Academic Press ISBN 9780124079014.

15. Nifurtimox Drug Information, Professional. www.drugs.com accessed 12th May, 2017. www.drugs.com/mmxx/nifurtimox.html.

16. Forsyth CJ, Hernandez S, Olmedo W, Abuhamidah A, Traina MI, Sanchez DR, et al (2016) Safety profile of nifurtimox for treatment of Chagas diseases in the United States. Clinical Infectious Disease 63 (8): 1056–1062.

17. Estani SS, Segura EL (1999) Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Memorias do Instituto Oswaldo Cruz 94: 363–365. PMID: 10677756

18. Agbo EC, Majiwa PAO, Claassen E, Roos MH (2001) Measure of molecular diversity within the Trypanosoma brucei subspecies Trypanosoma brucei brucei and T. b. gambiens as revealed by genotypic characterisation. Experimental Parasitology 99: 123–131 https://doi.org/10.1006/expr.2001.4666 PMID: 11846522

19. Caffrey CR, Scory S, Steverding D (2000) Cysteine proteinase of Trypanosome parasites: novel targets for chemotherapy. Current Drugs Targets 1(2): 155–162.

20. Lonsdale-Eccles JD, Grab DJ (1987) Trypanosoma brucei brucei. European Journal of Biochemistry 199(3): 467–475. PMID: 3319612

21. Grab DJ, Garcia-Garcia JC, Nikolksaia OV, Kim YV, Brown A, Prado CA, et al (2009) Protease Activated Receptor Signaling Is Required for African Trypanosome Transactivation of Human Brain Microvascular Endothelial Cells. PLOS Negl Trop Dis 3(7): e479. https://doi.org/10.1371/journal.pntd.0000479 PMID: 19621073

22. Ajibade PA, Kolawole GA. (2008) Synthesis, characterization, antiplasmodial and antitrypanosomal activity of some metal (III) complexes of sulfadiazine. Bulletin of the Chemical Society of Ethiopia 22(2): 261–268.
23. Papadopoulou MV. (2012) Novel 3-nitro-1H-1,2,4-triazole-based amides and sulphonamides as potential antitrypanosomal agents. Journal of Medicinal Chemistry 55(11): 5554–5565. https://doi.org/10.1021/jm300508n PMID: 22550999

24. Werbovetz KA, Sackett DL, Deflind D. (2003) Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulphanilamide (GB-11-5) against kinetoplastid parasites. Molecular Pharmacology 64(6): 1325–1333. https://doi.org/10.1124/mol.64.6.1325 PMID: 14645662

25. Otoguro K. (2008) Selective and Potent in vitro Antitrypanosomal Activities of Ten Microbial Metabolites. The Journal of Antibiotics, 61:372–378. https://doi.org/10.1038/ja.2008.52 PMID: 18667785

26. Ghosh M. (1984) Fundamentals of Experimental Pharmacology Scientific Book Agency, Calcutta 153–158

27. Baltz T, Baltz D, Giroud Ch, Crockett J. (1985) Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J 4: 1273–1277. PMID: 4006919

28. Lipinski CA, Lombardo L, Dominy BW, Feeney PJ (2001) Adv Drug Deliv Rev 46: 3–26. PMID: 11259830

29. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) J. Med. Chem 45: 2615–2623.

30. Faidallah HM, Rostom SAF, (2017) Synthesis, anti-inflammatory activity and COX-1/2 inhibition profile of some novel non-acidic polysubstituted pyrazoles and pyrano[2,3-c]pyrazoles. Archiv der Pharmazie 350: e1700025

31. Zhao Y, Abraham MH, Lee J, Hersey A, Luscombe NC, Beck G, et al (2002) Pharm Res 19: 1446–1457. PMID: 12425461